1

1 Systematic review and meta-analysis of COVID-19 vaccines safety, tolerability, 2 and efficacy among HIV-infected patients

Jacques L Tamuzi¹, Ley M Muyaya¹, Amal Mitra², Peter S Nyasulu ^{1,3*}

4 Author affiliations

- ⁵ ¹Division of Epidemiology, Faculty of Medicine and Health Sciences, Stellenbosch
- 6 University, Cape Town, South Africa
- ²Department of Epidemiology and Biostatistics, School of Public Health, College of
 Health Sciences, Jackson State University, Jackson, Mississippi, USA
- ⁹ ³Division of Epidemiology, School of Public Health, Faculty of Health Sciences,
- 10 University of the Witwatersrand, Johannesburg, South Africa

11

12

- 13 **Corresponding author: **Peter S. Nyasulu, Division of Epidemiology & Biostatistics,
- 14 Faculty of Medicine & Health Sciences, Stellenbosch University, Cape Town, South
- 15 Africa. Email: pnyasulu@sun.ac.za>

16		
17		

18 19

20

20

21

22

23

25

24

25

26

27

2

29 Abstract

30 **Objective**

To conduct a comprehensive systematic review and meta-analysis of all recommended SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) vaccines in people living with HIV (PLWH), as well as an overview of the safety, tolerability, and efficacy of the vaccines in PLWH.

35 Methods

We searched six databases, Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Medline, Medrxiv, Global research on COVID-19 database, and Google Scholar for studies investigating the effects of SARS-CoV-2 vaccines on PLWH. Results of the association were summarised by SARS-CoV IgG seroconversion and level, vaccines efficacy and tolerability. A meta-analysis was performed for studies, using random-effects model and a pooled RR with 95% CI was reported.

42 **Results**

Twenty-three of the 1052 studies screened met the inclusion criteria. The review 43 included 28, 246 participants among whom 79.55% (22,469/28, 246) were PLWH with 44 median CD4 ≥200 cells/µL. The pooled estimate of SARS-CoV-2 IgG seroconversion 45 and positive neutralizing antibodies after the second vaccination dose between PLWH 46 vs HIV negative were RR 0.95 (95%CI: 0.92 - 0.99, P = 0.006) and 0.88 (95%CI: 0.82-47 0.95, P = 0.0007), respectively. The mean difference of IgG antibodies level (BAU/ml) 48 was found higher in mRNA vaccines MD -1444.97 (95%CI: -1871.39, -1018.55). PLWH 49 with CD4 less than 500 cells/ µl had 15% risk reduction of neutralizing antibodies 50

51	response compared to those with CD4 $\geq \! 500$ cells/µl (P = 0.003). The SARS-CoV-2
52	vaccine effectiveness was 65% (95%CI: 56%-72%, P <0.001) among vaccinated
53	compared to unvaccinated PLWH. PLWH with CD4 count <350 cells/µl had lower
54	vaccine effectiveness compared to CD4 count \geq 350 cells/µl with 59% vs 72%,
55	respectively. Vaccine tolerability was the same between PLWH and HIV negatives.
56	Conclusion
57	According to our findings, PLWH with CD4 ≥200 cells/µL had lower immunogenicity and
58	antigenicity in COVID-19 vaccines than HIV negatives. Additional doses of SARS-CoV-
59	2 vaccination are needful in PLWH.
60 61 62	Key words: SARS-CoV-2, COVID-19, vaccines, efficacy, tolerability, HIV, PLWH
63 64	
65	
66	
67	
68	
69	
70 71	
72	
73	
74	
75	

4

76 **1. Background**

77

Nearly 37.6 million [30.2 million–45.0 million] people worldwide are infected with Human 78 79 Immunodeficiency Virus (HIV) [1], with Sub-Saharan Africa accounting for nearly 71% [2]. HIV and the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) are 80 the main syndemics of the twenty-first century. A recent study of over 15,000 cases of 81 82 COVID-19 in people living with HIV carried out by WHO revealed that PLWH were 13% more likely to be admitted to hospital with severe or critical COVID-19 after controlling 83 for age, gender, and comorbidities [3]. Furthermore, PLWH were more likely to die after 84 85 admission to hospital with COVID-19 with a 30% increased risk of death independent of age, gender, severity at presentation, and co-morbidities [3] and diabetes, high blood 86 pressure, male sex, or over 75 years old were each associated with an increased risk of 87 death [4]. Another study including 22 studies and 20,982,498 participants revealed that 88 PLWH had a significantly higher risk of SARS-CoV-2 infection than HIV-negative 89 90 individuals [5]. These multi-morbidities are driven by residual inflammation on ART and ongoing immune dysregulation [6] that could influence COVID-19 disease severity, the 91 durability of protective antiviral responses, and responsiveness to vaccination [7-9]. 92 93 Cellular immune deficiency and a low current or nadir CD4 cell count have been identified as potential risk factors for severe SARS-CoV-2 infection in PLWH, 94 irrespective of HIV virological suppression [10]. Conversely, persistent inflammation or 95 lower CD4-to-CD8 cell ratios among PLWH than among those without HIV could 96 increase susceptibility to viral infection [11, 12]. With emerging information on PLWH 97 98 with COVID-19 disease, a more pronounced immunodeficiency, defined as a current CD4 count <350/µL and a low CD4 nadir, has been associated with an increased risk 99

5

100 for severe COVID-19 and mortality [7]. Furthermore, HIV infection is associated with chronic inflammation and immune activation, which can accelerate the aging process of 101 the immune system, rendering it less responsive [13]. With daily antiretroviral therapy 102 (ART), significant immune dysfunction in PLWH can be reversed and prevented [14-16]. 103 Successful ART results in undetectable plasma HIV viraemia and a return to normal 104 CD4+ T cell counts [16, 17]. Despite ART, HIV-associated immune pathology is not 105 completely reversed, and many patients experience persistent T cell activation and 106 exhaustion for years [10, 16, 18, 19]. It is therefore likely that HIV-1 infection impairs the 107 SARS-CoV-2 immune response [20]. 108

109 Despite limited data, available information suggests current WHO-recommended COVID-19 vaccines are safe for people living with HIV [21]. Several SARS-CoV-2 110 111 vaccines have proved safe and efficacious in large clinical trials, and studies are ongoing to fully characterize their safety, tolerability, immunogenicity, and efficacy. 112 Although there are limited data in people with PLWH, mRNA, adenovirus-vectored DNA, 113 subunit (protein), and inactivated vaccines raise no safety concerns that are specific to 114 people with HIV [22]. Apart from this, the event of SARS-CoV-2 vaccination programs 115 need emphasizes in PLWH. The existing data are still controversial, and gaps remain 116 about the SARS-CoV-2 vaccines efficacy, safety, and tolerability in PLWH. Therefore, 117 there is an urgent need to conduct a comprehensive systematic review and meta-118 119 analysis that include all vaccination against SARS-CoV-2 in PLWH and provide an overview of safety, tolerability, and efficacy, describe the immune responses of SARS-120 CoV-2 vaccines in PLWH. Such knowledge is critical for future COVID-19 prevention in 121

6

PLWH during the pandemic, as well as informing vaccination strategies in this specificgroup.

124

- 125 **2. Methods**
- 126

127 **2.1 Overview**

128

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [23]. The review protocol was registered in the International Prospective Register of Systematic Reviews (review registration number: CRD42021228863) [24].

133 **2.2 Eligibility criteria**

134

Randomized trials, open-label and non-randomized, cohort study, case-control study, 135 and a cross-sectional study comparing different SARS-CoV-2 vaccines among which 136 nucleic acid vaccines among (mRNA, DNA vaccines, and other popular vaccine forms), 137 vector vaccines, inactivated vaccines, and live-attenuated vaccines between PLWH and 138 HIV negative people, or between PLWH with different CD4 count and/or interventions. 139 140 We included adults ≥18 years of age with HIV, with or without a history of SARS-CoV-2 infection. All the participants included in the intervention group had proof of approved 141 PLWH on highly active antiretroviral therapy (HAART). Additionally, PLWH with a 142 143 history of SARS-CoV-2 infection was confirmed by a previous SARS-CoV-2 PCR. The non-intervention group included HIV-negative subjects and/or HIV-infected (not 144

7

vaccinated or vaccinated with different SARS-CoV-2 vaccines, different from the
 intervention group).

147

148

149

150 **2.3. Electronic searches**

"Vaccines"[Majr]))

167

OR

151

We searched eligible studies including SARS-CoV-2 vaccines in PLWH, published in 152 English from January 2020 to November 2021 in different databases, Cochrane Central 153 154 Register of Controlled Trials (CENTRAL), PubMed, Medline. Medrxiv 155 (https://www.medrxiv.org), Global research on COVID-19 database (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-156 novel-coronavirus-2019-ncov) and Google Scholar. We also searched studies on 157 158 Medical Literature Analysis and Retrieval System Online, WHO International Clinical Trials Registry Platform (http://www.who.int/ictrp/en/), Global Alliance for Vaccine and 159 Immunisation, Coronavirus Clinical Studies or COVID-19 Prevention Network 160 161 (https://www.coronaviruspreventionnetwork.org/), ClinicalTrials.gov 162 (https://www.ClinicalTrials.gov/), Conference on Retroviruses and Opportunistic Infections(CROI), HIV i-base website and International AIDS Society (IAS). 163 The following search strategy was conducted in PUBMED and MEDLINE: "COVID-164 "HIV"[Mesh]) 165 19"[Mesh:NoExp]) OR "SARS-CoV-2"[Majr:NoExp]) AND OR "Immunosuppression"[Majr]) OR "Immunocompromised Host"[Majr]) AND 166

"Vaccination"[Mesh])

OR

"Immunization"[Majr])

OR

8

168 "Immunogenicity, Vaccine"[Mair]) AND "Safety"[Majr:NoExp]) OR "Treatment Outcome"[Majr]. The following keywords were used to search studies on other 169 databases and conference websites: "COVID-19 vaccines, SARS-CoV-2 vaccines, HIV, 170 171 HIV-infected patients, immune-depression, immunocompromised, efficacy, and tolerability". (SARS-CoV-2 vaccines OR COVID-19 vaccines) and (HIV-infected people 172 173 OR HIV OR immunocompromised OR immunosuppression) and (SARS-CoV-2-specific antibodies OR SARS-CoV-2 spike antibody responses). 174

175 **2.4. Study selection**

176

Duplicate studies were deleted electronically using EndNote's "Find Duplicates" tool, 177 178 and all studies collected from electronic databases using the search method were 179 imported into EndNote V.X9.5. The studies were manually reviewed again to identify and remove any additional duplicates. Two authors (JLT and LMM) choose papers that 180 181 are unrelated to one another. For any titles and abstracts that appear to fit the inclusion 182 requirements or where there is any doubt, complete articles were collected. Inappropriate population, improper intervention, improper comparison, inappropriate 183 outcome(s), inappropriate study design, and others were excluded. Following selection, 184 the two authors (JLT and LMM) discussed their choices and reached an agreement on 185 any disparities. If JLT and LMM authors were unable to achieve an agreement, PSN 186 was consulted. Cohen's kappa (k) statistics were used to calculate the overall 187 agreement rate before discrepant items are corrected. Following the resolution of 188 conflicts, the overall precision of searches was calculated by dividing the number of 189 190 studies included by the total number of studies screened after duplicates were removed. 191 The degree of agreement between the two independent data extractors (JLT and LMM)

9

was computed using kappa statistics to indicate the difference between observed and
expected agreements at random or by chance only. The following was how the Kappa
values were interpreted: (1) less than 0 equals less than chance agreement, (2) 0.01–
0.20: small agreement, (3) 0.21–0.40: good agreement, (4) 0.41–0.60: moderate
agreement, (5) 0.61–0.80: significant agreement, and (6) 0.8–0.99: practically perfect
agreement [25].

198

199

200 **2.5. Quality assessment**

201

Two reviewers (JLT and LMM) independently assessed the risk of bias in the included 202 papers. Any disagreement between the two reviewers about the risk of bias was settled 203 by a conversation with the third reviewer (PSN). For randomized controlled trials, the 204 205 Cochrane risk bias assessment tool was used [26]. Random sequence creation, concealment of allocations, blinding of participants and staff, blinding of outcome 206 207 assessments, insufficient data on outcomes, and selective reporting were all part of the risk assessment [26]. A bias risk assessment tool in non-randomized intervention 208 studies (ROBINS-I) was used to assess the risk of bias in included non-randomized 209 210 studies, including bias due to confounding (pre-intervention), bias in the selection of study participants (pre-intervention), and bias in the classification of interventions 211 (intervention), bias due to deviations from the intended intervention (post-intervention), 212 bias due to missing data (post-intervention), bias in the measurement of outcomes 213 214 (post-intervention), bias in the selection of reported outcomes (post-intervention) and

10

overall bias risk [27]. We assessed the risk of bias as the low, moderate, serious, critical
risk of bias, and no information [27].

217

218 **2.6. Data abstraction**

219

Data were extracted by two independent reviewers (JLT and LMM) using a 220 standardized data abstraction form, developed according to the sequence of variables 221 222 required from the primary studies. Disagreements in data abstraction between the 223 reviewers were resolved by a third independent reviewer (PSN). All data were extracted into an Excel worksheet template. Data were extracted on the following: author's first 224 225 name, publication date and location (country in which the research was conducted), 226 methods (study design, study setting, sample size, total study duration, withdrawal, and 227 date of study), participants (sample size, gender, mean age, median and ranges CD4 count, HIV viral load (suppressed or not suppressed), inclusion and exclusion criteria), 228 229 interventions (COVID-19 nucleic acid vaccines, vector vaccines, inactivated vaccines 230 and live attenuated vaccines), and comparisons included PLWH with placebo, no intervention or different vaccines compared to the intervention group. We also included 231 as comparisons HIV-negative with placebo, no intervention, and same vaccine as the 232 233 intervention group.

The primary and secondary outcomes were specified and collected, and time points were reported. We included primary outcomes among which seroconversion for SARS-CoV-2 neutralizing antibody after the first and the second doses of the vaccines, IgG antibody level after the first and second vaccines doses, anti-SARS-CoV-2 neutralizing antibodies, SARS-CoV-2 vaccines effectiveness, local and systematic reactions after

11

the first and second doses. The second outcomes included PLWH subgroups based on
 CD4 count < 200 vs ≥200 cells/µl; <350 vs ≥350 cells/µl; and <500 vs ≥500 cells/µl.

242 2.7. Interventions

243

The interventions included any type of SARS-CoV-2 vaccine regardless of dose (1, 2, or 3 doses), administration routes, and duration. Based on the mechanism of action of SARS-CoV-2 vaccines, we grouped them as inactivated or weakened virus vaccines, protein-based vaccines, viral vector vaccines, RNA and DNA vaccines administered as primary series of one or two doses according to vaccines protocols.

Inactivated vaccines: Are kind of whole-cell vaccine in which the pathogenic materials of the causing pathogen or a very similar one are destroyed by chemicals (such as formaldehyde or beta-propiolactone), radiation, or heat. This demolishes the pathogen's ability to replicate while keeping its immunization potential [28, 29]. One of the inactivated vaccines manufactured for the COVID-19 infection is CoronaVac® or Sinovac® containing the inactivated virus and aluminium as an adjuvant.

Protein subunit vaccines: Subunit vaccines merely consist of the immunogenic proteins derived from a pathogen, which can stimulate the host's immune system [29]. The proteins can be easily produced by recombinant DNA techniques [29, 30]. It was shown that protein subunit vaccines together with adjuvants generated a potent response against SARS-CoV-2 [29]. The vaccines have good safety profiles since there are no live components; reactogenicity and side effects are mainly related to adjuvants [31]. In the case of Novavax, neutralizing antibodies (nAbs) was 100-times higher after

12

the second dose and 4-times higher than symptomatic outpatients after 35 days [29,32].

Viral vector vaccines: A viral vector is a modified virus used to deliver a target gene to 264 the host cell. Modified virus is obtained by inserting an immunogenic part of the desired 265 virus, which is the S protein gene for SARS-CoV2 into a safe and non-pathogenic virus 266 267 as a vector [29, 33]. Subunit Vaccines targets are S proteins in the development of 268 subunit vaccines, which would lead to inhibition of the binding of the viruses to the host angiotensin-converting enzyme 2 (ACE2) [34, 35]. There are two types of viral vector 269 270 vaccines: non-replicating and replicating. The non-replicating vectors do not have genes 271 responsible for replication, so they cannot replicate and only produce virus antigens. On 272 the other hand, replicating vectors, multiply in the body and infect other cells, causing all 273 cells to produce antigens [36, 37]. Viral vector vaccines include ChAdOx1 nCoV-19, Sputnik V, Ad26.COV2-S, Ad5-nCoV, and others. 274

Nucleic Acid Vaccines: are usually made of mRNA molecules encapsulated in lipid 275 276 nanoparticles (LNP). LNP facilitates mRNA penetration into the host cell so that the translation process can be initiated [28, 29]. The cellular immune response is seen 277 278 when the S proteins are presented to immune cells either by the MHC class I or II complex, activating both CD4⁺ and CD8⁺ cells [29]. The salient features of mRNA 279 vaccines are: (i) Translation of mRNA occurs in the cytoplasm to avoid the risk of any 280 genome integration. (ii) Both T cell and antibody responses are triggered. (iii) Rapid 281 development and large-scale mass production can be achieved [31]. Two important 282 mRNA vaccines for COVID-19 are mRNA-1273 by Moderna TX, Inc, BNT162b1 by 283 BioNTech- Fosun Pharma-Pfizer, and LNP-nCoVsa RNA. A DNA vaccine is another 284

13

type of nucleic acid vaccine. DNA vaccines are produced by inserting the gene of an
antigenic protein into a bacteria-derived plasmid and delivering it to the host cells. The
protein-producing machinery of the host cell will translate DNA to mRNA and finally, a
protein that can stimulate the immune system. **2.8. Outcomes**

- 290
- 291 **2.8.1.** Primary outcomes
- 292

IgG antibody seroconversion for SARS-CoV-2 after the first and the second doses

of the vaccines: defined as numbers or proportions of IgG seropositivity status such as
 ELISA specific SARS-CoV-2 spike receptor-binding domain (RBD) antibody responses
 among PLWH and HIV negatives.

IgG antibody level after the first and second doses: measured total binding antibodies against SARS-CoV-2 nucleocapsid (N) and spike receptor-binding domain (RBD). Results reported in arbitrary units (AU)/mL were converted to binding antibody units (BAU/ml).

301 SARS-CoV-2 neutralizing antibodies (NAbs) after the second vaccine dose: 302 Antibodies that bind to Spike, a large homotrimeric glycoprotein studded across the viral 303 surface, have been shown to neutralize SARS-CoV-2 [35, 36]. NAbs are critical for virus 304 clearance and SARS-CoV-2 protection [37]. This outcome included numbers and 305 proportions of PLWH vs HIV negatives with high titers of neutralizing anti-S antibodies.

SARS-CoV-2 vaccine efficacy (%) was defined as (1– Relative Ratio) ×100, where RR
 is the relative risk of Covid-19 illness including mild, moderate, severe, and critical

14

cases confirmed by Polymerase chain reaction (PCR) among vaccinated and
 unvaccinated PLWH.

Local and systematic reactions after the first and second doses: Numbers and

- proportions of PLWH vs HIV negatives with local and systemic AEs.
- 312 2.8.2. Secondary outcomes

The outcomes included PLWH subgroups based on positive neutralizing antibodies with CD4 count < 200 vs \geq 200 cells/µl and <500 vs \geq 500 cells/µl: and vaccines effectiveness <350 vs \geq 350 cells/µl. We also compared IgG antibody levels between different types of vaccines.

317

318 **2.9. Statistical analysis**

319

The meta-analysis was carried out with the review manager software (Revman version 320 321 5.3) [38] and complementary analyses were undertaken with ProMeta version 3 [39]. We presented data from eligible studies in evidence tables and figures (map, flow 322 diagram, forest plots, funnel plot, and meta-regression figures). The relative risks (RR) 323 324 with 95% CI of the effect size for binary outcomes and the mean difference (MD) with 95% CI were reported for continuous outcomes. In cases where continuous outcomes 325 326 were reported in median (IQR), the conversion to mean (SE) was undertaken according 327 to [40]. We converted AU/mI to BAU/mI with the conversion factor as follows: 1 BAU/mL 328 = $0.142 \times AU/mL$. Pooled results from continuous outcomes have been expressed in BAU/mL [41]. 329

15

330 Based on the type of SARS-CoV-2 vaccines (viral vector, protein subunit, mRNA, DNA, and inactivated vaccines), we built different forest plots including subgroup analysis of 331 vaccines type for the following outcomes: RBD IgG seroconversion, IgG antibody level, 332 333 neutralization antibodies responses, vaccine efficacy, SARS-CoV-2 post-vaccination, local reaction, and systemic reactions. As statistical heterogeneity was significant 334 because of different vaccines groups, the random-effect model (Mantel-Haenszel or 335 inverse variance methods) was adopted in this meta-analysis. Heterogeneity between 336 the results of the primary studies was assessed using Cochran's Q test and quantified 337 with the I-squared statistic. A probability value less than 0.1 (p<0.1) was considered to 338 suggest statistically significant heterogeneity [42]. Heterogeneity was considered low, 339 moderate, and high when the values are <25%, 25% to 75%, and >75%, respectively 340 [42]. In case of high heterogeneity (above 90%) after subgroup analysis, the results 341 were reported by type of vaccines or individual studies. 342

We computed Egger's regression and Begg Mazumdar's rank correlation test to 343 344 evaluate possible publication bias. We conducted a sensitivity analysis to assess the robustness of our pooled RR of RBD antibody responses after the first and the second 345 dose of SARS-CoV-2 vaccines among PLWH and HIV-negative people. The guality of 346 evidence was assessed for each study using Grading of Recommendations, 347 Assessment, Development and Evaluation (GRADE) criteria [43]. The Grade was 348 349 assessed through the study design and risk of bias, inconsistency, indirectness, imprecision, and publication bias [43]. 350

351 **3. Results**

16

353 **3.1. Characteristics of included studies**

354

355 A total of 1122 studies were identified in the databases, of which 70 were eliminated as duplicates, 1052 by reading titles and abstracts, 65 by reading the full text, and 42 were 356 357 excluded with reasons as mentioned in Figure 1. Twenty-three studies were selected 358 for the analysis [16, 44-65]. The review included 28, 246 participants among whom 359 79.55% (22,469/28, 246) were PLWH. All studies included participants 18 years and 360 above. All the medians' CD4 count was≥ 200 cells/µl (Supplementary material: Table 1). Sixteen studies reported the HIV viral load, among them, six studies included PLWH 361 362 with viral load < 50 copies/ml [16, 45, 49, 51, 53, 54] and nine other studies included PLWH with viral load 58.1 to 95% suppressed [44, 46, 52, 55, 56, 58, 60, 61, 63, 65] 363 (Supplementary material: Table 1). 364

The selected articles reported data from United States of America (n = 4) [48-50, 55]. 365 China (n=5) [52, 54, 59, 61, 64], South Africa (n = 3) [45, 46, 57], United Kingdom (n = 366 367 2) [16, 53], Canada (n=2) [47, 51], Italia (n=1) [58], Brazil (n =1) [56], Germany (n =1) [60], Israel (n = 1) [44], Sweden (n=1) [64], Taiwan (n=1) [65] and Russia (n = 1) [62] 368 (Figure 2). Ten studies used randomized control designs [16, 45, 46, 49, 50, 53, 54, 64, 369 370 64, 65], eight studies used prospective cohort designs [44, 47, 48, 51, 52, 56-58], two retrospective cohort studies [62, 63], two cross sectional studies [59, 61] and one case 371 control study [55] (Supplementary material: Table 1). Eleven studies included mRNA 372 373 vaccines among which BNT162b2 mRNA, Vaccine, mRNA-1273 (100 µg) administered 374 intramuscularly (IM) as a series of two doses (0.5 mL each), given 28 days apart [44, 47, 48, 50, 51, 53, 55, 58, 60, 63, 64], six studies included inactivated vaccines 375 including CoronaVac (3 µg/0.5 mL), BBIBP-CorV (4 µg/0.5 mL) or Sinovac (0.5 ml) 376

17

given intramuscularly [52, 54, 56, 59, 61, 64], seven studies included viral vector vaccines among which ChAdOx1 nCoV-19 with two doses (5 × 1010 vp) was given 4-6 weeks apart, Ad26.COV2.S [16, 45, 49, 51, 57, 62, 63] and two study included sub unit protein vaccine NVX-CoV2373 (5 μ g (sub unit) of recombinant spike protein with 50 μ g of Matrix-M1 adjuvant) administered two intramuscular injections, 21 days apart and two standard doses of 15 mcg MVC-COV1901, administered 28 days apart via IM injection [46, 65] (**Supplementary material: Table 1**)

In terms of the bias risk analysis of the domains considered in the Cochrane 384 385 Collaboration tool [25], all eight randomized control trials [16, 45, 46, 49, 50, 63-65] showed an unclear for allocation concealment bias risk (Supplementary material: 386 Table 2). Four papers reported a high risk of bias for random sequence generation as 387 388 well as masking of participants and professionals [16, 63-65], five trials showed a low risk of blinding of participants and personnel [45, 46, 49, 50, 65], one study reported a 389 high risk of blinding of outcomes assessment [63], two studies reported a low risk of 390 other bias [49, 50], and others reported a high risk. In other domains, all studies 391 presented low bias risks (Supplementary material: Table 2). Regarding the risk of bias 392 of non-randomized studies, sixteen studies were assessed with the ROBIN-I bias tool 393 assessment [26]. Among them, seven were rated as low-moderate for the overall 394 ROBIN-I [44, 51, 52, 55, 57, 58, 60], four studies were low-serious [53, 54, 56, 62], one 395 study was moderate-serious [61], another study was Serious-Critical [48] and two 396 studies were critical [47, 59] (Supplementary material: Table 3). 397

398 **3.2.** Meta-analysis

18

400 **3.2.1. IgG seroconversion after 1st vaccination dose:**

Figure 3 shows a comparative forest plot analysis of IgG seroconversion after the first 401 SARS-CoV-2 vaccines across published eight studies [16, 44, 45, 49, 52, 56] looking at 402 403 the RR between 935 PLWH with CD4 \geq 300 cells/µl and 1013 HIV negative people. Overall, the random-effects model presented a RR of 0.83 (95%CI 0.65-1.06, 1948) 404 participants, P = 0.14, $I^2 = 85\%$). The results presented by type of vaccine showed 405 SARS-CoV-2 inactivated vaccines administered in PLWH had 53% risk reduction of IgG 406 seroconversion compared to HIV negative people. In contrast mRNA and viral vaccines 407 408 did not have different seroconversion between PLWH and HIV negative people with RR 1.00(95%CI: 0.79-1.27) and 1.00(95%CI: 0.90-1.12), respectively. 409

410

411 **3.2.2. IgG seroconversion after 2nd vaccination dose:**

412 The pooled seroconversion results after SARS-CoV-2 vaccination second dose 413 between 1885 PLWH and 7768 HIV negative people showed statistically difference between the two groups RR 0.95 (95%CI: 0.92 - 0.99, P = 0.006), with the test for 414 subgroup differences $I^2 = 41.3\%$ (p = 0.16) (**Figure 4**). IgG seroconversion after the 415 second vaccination dose was not statistically different between PLWH and HIV negative 416 people for mRNA and protein subunit vaccines with RR 0.98 (95%CI: 0.96-1.00, P = 417 0.06) and 0.91(95%CI: 0.42-1.98, P = 0.81), respectively. In contrast, viral vector and 418 419 inactivated vaccines reported statistically lower IgG seroconversion after second vaccination dose 420

19

among PLWH with RR 0.93 (95%CI: 0.88-1.00, P = 0.04) and 0.90(0.81-0.99, P = 0.03),
respectively.

423

424 3.2.3. IgG antibody level after the first dose of SARS-CoV-2 vaccines (BAU/ml) 425

Figure 5 reported IgG antibodies level after the first dose of SARS-CoV-2 vaccines. The pooled result including eight studies [44, 45, 51-54, 56, 60] has shown that the mean difference (MD) IgG antibody level (BAU/ml) did not differ between 643 PLWH and 762 HIV negatives after the first dose of SARS-CoV-2 vaccines MD-0.02 (95%CI: -0.09-0.05, P = 0.58). The test of heterogeneity between studies was high ($I^2 = 83\%$). However, the test for subgroup difference was not statistically significant ($I^2 = 33.6\%$, P = 0.21).

433

3.2.4. IgG antibody level (BAU/mI) after the second dose of SARS-CoV-2 vaccines 434 Twelve studies reported IgG antibody levels after the second SARS-CoV-2 dose 435 436 (Figure 6). As heterogeneity was high between included studies and /or vaccines type, the results were reported narratively. Eight studies out of eleven showed a statistically 437 438 significant decrease of the mean difference IgG antibody level after the second SARS-439 CoV-2 dose (BAU/ml) among PLWH compared to HIV-negative people. The highest and lowest statistically significant mean difference IgG antibody level (BAU/mI) after the 440 second SARS-CoV-2 dose were found in mRNA vaccines MD -1444.97 (95%CI: -441 442 1871.39, -1018.55) [58] and MD -0.80(95%CI: -0.90, -0.70).

443 **3.2.5. SARS-CoV-2 vaccines effectiveness**

444	Figure 7 described the RR of COVID-19 vaccines effectiveness among 20,314
445	vaccinated and unvaccinated PLWH. The pooled results included four studies [46, 49,
446	50, 62] showed that that vaccine effectiveness was 65% (95%CI: 56%-72%, P <0.001)
447	among vaccinated compared to unvaccinated PLWH, with the test for subgroup
448	differences $I^2 = 0\%$ (P = 0.47).
449 450 451 452 453	3.2.6. Vaccine's effectiveness based on CD4 count The pooled SARS-COV-2 vaccines effectiveness of 13,547 vaccinated and
454	unvaccinated PLWH with CD4 count <350 vs ≥ 350 cells/µl was 69 % (95%CI: 58%-
455	78%, P < 0.001) (Figure 8). However, PLWH with CD4 count <350 cells/µl had lower
456	vaccine effectiveness compared to CD4 count \geq 350 cells/µl with 59% vs 72%,
457	respectively. The test for subgroup differences was not statistically different between the
458	two groups ($I^2 = 23.2\%$, P = 0.25) (Figure 8).
459	
460	
461 462	3.2.7. SARS-CoV-2 vaccines neutralizing antibodies response after the second
463	dose
464	Figure 9 reported the pooled neutralizing antibodies response after the second dose of
465	SARS-CoV-2 vaccines between 769 PLWH and 613 HIV-negative people. PLWH had
466	12% risk reduction of neutralizing antibodies response compared to HIV negative
467	people with RR 0.88 (95%CI 0.82-0.95, 1,059 participants, P = 0.0007). mRNA vaccines
468	had statistically significant lower neutralizing antibodies response RR 0.89 (95%CI 0.84-
169	0.93. $P < 0.0001$). In contrast, neutralizing antibodies response between PLWH and HIV

21

negative people was not statistically significant with inactivated vaccines, RR 0.88 (95%CI 0.77-1.02, P = 0.10).

472

473 **3.2.8.** Any local reaction after the first SARS-CoV-2 vaccines dose:

The meta-analysis including five studies with local reactions after the first SARS-CoV-2 vaccines dose did not show statistically significant between PLWH and HIV negative people with RR 0.98 (95%CI: 0.71 - 1.36, 1,688 participants, P = 0.91), with the test for subgroup differences $I^2 = 80.9.0\%$ (p = 0.001). However, Levy and al. showed significant local reactions among HIV negative people RR 1.59 (95%CI: 1.22-2.07, P = 0.0006) (**Figure 10**).

480

481 **3.2.9.** Any systemic reaction after the first SARS-CoV-2 vaccines dose:

Heterogeneity between protein subunit, mRNA, and the viral vector vaccines was high in the meta-analysis of systemic reactions after the first SARS-CoV-2 vaccines dose, therefore we reported the results separately. mRNA vaccine reported a lower risk of systemic reactions after the first SARS-CoV-2 vaccine among PLWH compared HIV negative people RR 0.41 (95%CI: 0.28 – 0.58). In contrast, both inactivated and viral vector vaccines reported the same risk of systemic reaction after the first dose of SARS-CoV-2 vaccines among PLWH and HIV-negative participants.

489

490 **3.2.10.** Any local reaction after the second SARS-CoV-2 vaccines dose:

491 The estimated RR of local reactions after the second SARS-CoV-2 vaccines dose 492 between 838 PLWH and 4, 533 HIV-negative people was not statistically different RR

22

493	0.97 (0.82 – 1.14, P = 0.06), with the test for subgroup differences $I^2 = 15.9\%$ (Figure
494	12).
495	
496	3.2.11. Any systemic reaction after the 2 nd dose
497	The pooled results of systemic reactions after the 2 nd dose of SARS-CoV-2 vaccines
498	were not statistically significant between 591 PLWH and 942 HIV negative people RR
499	0.97 (95%CI: 0.82-1.14, P = 0.71) (Figure 13). In contrast, PLWH had less systemic
500	reaction after the second dose compared to HIV negative subjects' RR 0.69(95%: 0.53-
501	0.91, P = 0.009) (Figure 13).
502 503	3.2.12. IgG seroconversion based on CD4 count (<500 vs ≥500 cells/μL) among PLWH
504	The pooled result of IgG seroconversion based on CD4 count being less and above or
505	equal to 500 cells/ μL included 638 PLWH and five studies [47, 56-58, 61] (Figure 14).
506	The result revealed no statistically significant results between the two PLWH groups RR
507	(0.79, 95%CI: 0.63-1.00, $P = 0.05$) (Figure 14). Heterogeneity was high between the
508	vaccine types ($I^2 = 88$, P <0.001), however, the test for subgroup analysis was not
509	statistically significant between the vaccine groups ($I2 = 24.2\%$, $P = 0.27$) (Figure 14).
510 511	3.2.13. IgG seroconversion based on CD4 count (<200 vs ≥200 cells/μL) among PLWH
512	
513	Figure 15 depicted the overall results of IgG seroconversion among 294 PLWH based
514	on CD4 count <200 or ≥200 cells/µL. The result did not show a statistically significant
515	difference between the two groups RR 0.68 (95%: 0.32-1.45, P = 32). The test for
516	subgroup analysis was not statistically different between the two groups (I2 = 61, 6%, P

517 **=** 0.11).

23

3.2.14. SARS-CoV-2 vaccines neutralizing antibodies response among PLWH (<500 vs ≥500 cells/µL)

The pooled result of neutralizing antibodies response of three studies [56, 58, 60] revealed that PLWH with CD4 less than 500 cells/ μ L had 15% risk reduction of neutralizing antibodies response compared to those with CD4≥500 cells/ μ L (RR 0.85, 95%CI: 0.77-0.95, P = 0.003) (**Figure 16**).

524 525

3.3. Sensitivity analysis

To assess the robustness of our pooled RR of IgG seroconversion, IgG antibodies level, neutralizing antibodies response, vaccine efficacy, local and systemic reactions after the first and second dose of SARS-CoV-2 vaccines, we performed a sensitivity analysis. This analysis revealed that the overall estimates of IgG seroconversion, IgG antibodies level, neutralizing antibodies response, local and systemic reactions were robust and were not influenced by a single study. However, the overall estimate of vaccine efficacy was influenced by [62].

533

534 **3.4. Meta-regression**

⁵³⁵ Univariate meta-regression analyses were performed to investigate whether the median ⁵³⁶ age and CD4 account were associated with the SARS-CoV-2 IgG antibodies level effect ⁵³⁷ estimates. Twelve studies [16, 44, 45, 51-56, 58, 60, 61] reporting the median age of ⁵³⁸ CD4 count were included. Univariate meta-regression showed than neither the median ⁵³⁹ age nor CD4 cells/ µI were associated with the SARS-CoV-2 IgG antibodies level

24

(BAU/ml) effect estimates with the coefficient =0.15 and P= 0.739 (**Figure 17 a**) and coefficient = -0.00 and P = 0.910 (**Figure 17b**), respectively.

542 **3.5.** Publication bias

As one of the pooled results included more than 10 studies, we built the funnel plot and 543 Egger's linear regression and Begg and Mazumdar's rank correlation tests were used to 544 545 assess publication bias. The symmetry of the funnel plots was examined to search for possible publication bias or even heterogeneity. The funnel plot for IgG seroconversion 546 547 after the second dose of SARS-CoV-2 vaccines and IgG antibodies level were both asymmetrical around a single peak (Figure 16). The result of Egger's test for small-548 study effects showed that there was a statistically significant publication bias in 549 550 estimating IgG seroconversion after the second SARS-CoV-2 vaccination with Egger's linear regression (t = -3.53 and P = 0.004) and Begg and Mazumdar's rank correlation 551 test, Z value for Kendall's tau = -1.53, p = 0.112. In the same, the Egger's linear 552 regression for IgG antibodies level (t = -3.34 and P = 0.007) and Begg and Mazumdar's 553 rank correlation test, Z value for Kendall's tau = -0.85, p = 0.393. This means that the 554 weighted regression test detected statistical evidence of bias. 555

556

557 **4.** Discussion

558

This systematic review and meta-analysis assessed SARS-CoV-2 vaccines' efficacy, safety, and tolerability in PLWH. The review included twenty-three studies and 28, 246 participants among whom 79.55% (22, 469/28, 246) were PLWH. The studies included adults with age \geq 18 years. All studies included PLWH with median CD4 count \geq 200 cells/µL. Sixteen out of twenty-three studies reported the HIV viral load. Among them,

25

six studies included PLWH with viral load < 50 copies/ml [16, 45, 49, 51, 53, 54] and ten
others included PLWH with viral load 58.1% to 95% suppressed [44, 46, 52, 55, 56, 58,
60, 61, 63, 65].

567 Our findings highlighted that PLWH had lower IgG seroconversion and neutralizing antibodies response after the second vaccination dose compared to HIV negatives. 568 569 However, neutralizing IgG antibodies were not different between the two groups for 570 inactivated vaccines. The review also found that IgG antibody levels after the second dose of SARS-CoV-2 vaccines were lower in PLWH as reported in 8 out of 12 studies. 571 572 However, three studies involving mRNA vaccines and heterogeneous (mRNA and viral vector vaccines) showed statistically higher MD than viral vector and inactivated 573 574 vaccines [53, 58, 60]. Meta-regression revealed no relationship between the level of IgG 575 antibodies and the median CD4 count greater than 280 cells/L or age greater than 18 years. When compared to other SARS-CoV-2 vaccines, mRNA vaccines elicited a high 576 level of IgG antibodies [66]. By the way, mRNA vaccines produced higher levels of 577 antibodies after the second dose than the other vaccine groups. After the first dose of 578 SARS-CoV-2 vaccination, IgG antibody levels in PLWH and HIV-negative participants 579 580 were the same. This is significant because previous research has shown that SARS-CoV-2 IgG seroconversion in PLWH was quickly lost, implying that PLWH were at a 581 disadvantage following COVID-19 vaccination [67]. According to a recent study, data 582 583 are currently insufficient to determine whether there is a significant decline in vaccine effectiveness against any form of clinical illness caused by SARS-CoV-2 infection 584 beyond 6 months after vaccination [68]. According to Israeli data, approximately 40% of 585 586 breakthrough infections occur in immunocompromised individuals [68].

26

587 Our study also revealed that IgG seroconversions between <500 vs ≥500 cells/µl or <200 vs ≥200 cells/µl were not different among PLWH. However, the neutralizing 588 antibodies response was lower in PLWH with CD4 count <500 cells/µl than ≥500 589 590 cells/µl. This should be taken in the context of a small sample size and missing data to assess the impact of lower CD4 counts (< 200 and <500 cells/µL) on SARS-CoV-2 591 vaccines immunogenicity and antigenicity in PLWH. It should be noted that our included 592 studies had the median CD4 > 200 cells/µl. Based on low immunogenicity and 593 antigenicity among PLWH and knowing that severe immunosuppression due to 594 HIV/AIDS is defined as a current CD4 count of <200 cells/µl for adults or children [22]. 595 Besides, the effectiveness of the SARS-CoV-2 vaccine was 65% between vaccinated 596 and unvaccinated PLWH. In the same, the SARS-CoV-2 among PLWH with CD4 count 597 598 \geq 350 cells/µl was higher than those with CD4 count < 350 cells/µl. Our results may not be generalizable to PLWH with CD4+ T-cell counts <200 cells/ µl as the sample size 599 was very small in this specific subgroup and the vaccine effectiveness outcome was 600 601 highly influenced by one study including vector viral adenovirus vaccine [62]. Besides, non-replicating vaccines, including those licensed for SARS-CoV-2 can be given to all 602 PLWH, although replicating vaccines should be avoided in those with CD4 count < 200 603 cells/µl [16, 49]. 604

605 Currently, CDC is recommending that moderately to severely immunocompromised 606 people receive an additional dose [69]. The U.S Food and Drug Administration also 607 authorized the use of an additional dose of COVID-19 vaccines in people who are 608 immunocompromised [70, 71], reporting that a booster dose would provide enhanced 609 protection against COVID-19 in PLWH. The new recommendations are only about a

27

610 third dose to increase the level of protection from COVID-19 for PLWH with CD4 count < 200 cells/µl [72]. As a general consideration, PLWH with CD4 counts <200 cells/ µl 611 who are not on ART should first receive ART before vaccination [73]. Vaccination 612 613 should be deferred until a clinically significant immune reconstitution has been achieved, preferentially after the CD4 cell count has increased >200 cells/mm3 [73]. In 614 fact, there are several reasons why COVID-19 vaccine booster doses may be needed in 615 PLWH: (i) waning protection against infection or disease, in particular severe disease, 616 over time (i.e., waning immunity), (ii) reduced protection against a variant(s) of concern 617 (VOC), or (iii) inadequate protection from the currently recommended primary series for 618 some risk groups for which evidence from long term SARS-CoV-2 IgG seroconversion 619 is lacking [73]. Additionally, evidence shows PLWH with a low CD4 count, high HIV viral 620 621 loads, and lack of ART use respond less strongly to vaccination, which is why they may be offered a third dose [22]. In the same line, vaccination responses for PLWH may also 622 be suboptimal despite ART, and the duration of seroprotection was shorter in PLWH 623 624 [74-76], necessitating adjusted vaccine schedules or a booster [16, 77]. However, the rationale for booster doses may differ by vaccine product, epidemiological setting, risk 625 group, and vaccine coverage rates [73]. According to a recent study, PLWH with well-626 controlled viral loads on antiretroviral therapy and CD4+ T-cell counts in the healthy 627 range may not need a third COVID-19 vaccine dose as part of their initial immunization 628 629 series, though other factors such as older age, co-morbidities, vaccine regimen type, and vaccine response durability will influence when this group may benefit from 630 additional doses [51]. Further, ART should be initiated as soon as possible, not only to 631 632 preserve immune function and avoid secondary HIV transmission but also to avoid the

28

633 complicated interaction between HIV infection and the above factors [78, 79]. While antibody levels may be measured, without a clear understanding of the correlates of 634 protection against severe disease and the interaction of immune suppression with 635 636 measured immune responses, clinical inferences based on the measurement of antibody levels in persons who are immunosuppressed are difficult [80]. For instance, 637 low antibody levels may not denote poor protection against severe disease; and 638 conversely, high antibody levels in a person unable to generate a commensurate 639 cellular response may not denote good protection against severe disease [80]. Our 640 review has shown high variability of anti-RBD levels between mRNA, viral vector, and 641 inactivated SARS-CoV-2 vaccines after the second dose even though anti-RBD levels 642 were quite constant after the first dose. This high variability can be due to the presence, 643 644 in naturally infected individuals, of neutralizing antibodies other than anti-RBD (such as antibodies that recognize the N-terminal domain of the S protein) [41]. Moreover, the 645 emergence of VOC, i.e., variant strains that carry mutations potentially able to reduce 646 the neutralizing efficacy after either natural infection or vaccination has further increased 647 the risk of a diminished efficacy [81]. This is important to emphasize that males were 648 predominant in most of the included studies. However, a study reported no differences 649 650 by age and gender were not significant with anti-RBD median values were evaluated in comparison with neutralizing titers ≥1:20 or ≥1:80 [41]. Besides, univariate meta-651 652 regression has shown that IgG seroconversion was not correlated with the median age of 25 to 60 years and CD4 > 280 cells/ μ l. 653

654 Our study also showed that SARS-CoV-2 vaccines tolerability was the same between 655 PLWH and HIV negatives in point of view local reactions after the first and second

29

656 doses of SARS-CoV-2 vaccines and systemic reactions after the 2nd dose. Local reactions after the second dose of SARS-CoV-2 vaccines, on the other hand, varied 657 significantly between studies, and the results were not consistent enough due to the 658 659 small number of studies. Our findings showed that after the second dose of SARS-CoV-2 viral vector vaccine in PLWH, local reactions were significantly reduced [16, 45]. 660 Similarly, mRNA vaccine significantly reduced systemic reactions after the first SARS-661 CoV-2 vaccines dose in PLWH [44], while HIV negative people had higher systemic 662 reactions after the first SARS-CoV-2 protein subunit vaccines dose than PLWH [46]. 663 However, those results should be considered with caution because of the small sample 664 size among included studies. Concerns for adverse effects (AEs) significantly impact 665 persistent vaccine hesitancy among PLWH. Studies have shown a low level of SARS-666 667 CoV-2 vaccines acceptability among PLWH compared to participants not living with HIV. In China (57.2% vs 91.3%) [82, 83], Canada (65.2% vs 79.6%) [84], India (46.1% 668 vs 74.5) [83, 85], in French (71.3% vs 58.9%) [83,86]. Our findings may play a 669 670 substantial role to enhance COVID-19 vaccination among PLWH as fears of severe side effects are a major concern in this group population [86]. 671

According to our knowledge, this is the first systematic review and meta-analysis to investigate the safety, tolerability, and efficacy of SARS-CoV-2 vaccines in HIV-infected patients. Little research has been conducted on this topic because PLWH are a unique population due to the severity and mortality rates of COVID-19. The review strength is the fact that the sensitivity analysis, the overall estimate of RR of IgG seroconversion, IgG antibodies levels, neutralizing antibodies response, local and systemic reactions after the first and second doses of SARS-CoV-2 vaccines was robust and was

30

unaffected by a single study. However, the vaccine efficacy was influenced by a singlelarge sample size study [62].

681 Publication was not well controlled with Egger's linear regression test (t = -3.53 and p =682 (0.004) and Begg and Mazumdar's rank correlation test (Z value for Kendall's tau = -1.53) and p = 0.112) for IgG seroconversion after the second dose of SARS-CoV-2 vaccines 683 684 and Egger's linear regression test (t = -3.37 and p = 0.007) and Begg and Mazumdar's 685 rank correlation test (Z value for Kendall's tau = 0.85 and p = 0.393) for IgG antibodies level after the second dose of SARS-CoV-2 vaccines. However, the review finding is 686 687 limited by the nature of included studies. Most studies included had small sample sizes, and long-term SARS-CoV-2 IgG seroconversion, level, neutralizing antibodies, and 688 vaccine efficacy was not assessed. Larger studies will be needed to confirm and extend 689 690 the findings, particularly in the case of IgG antibodies level after the second dose of SARS-CoV-2 vaccination in PLWH. CD4 and CD8 counts should be prioritized, as 691 SARS-CoV-2 vaccine immune responses are dependent on CD4 counts in PLWH. 692 Further research into suppressed versus non-suppressed HIV viral load is also required. 693 694 In the same line, more research on PLWH who are not receiving antiretroviral therapy and/or have low CD4+ T-cell counts is required. 695

Besides. further consideration infection 696 is that persistent in severely immunocompromised PLWH (CD4 count < 200 cells/ μ L) may allow the emergence of 697 variant strains of SARS-CoV-2 (variants of concerns) with the potential to escape 698 immune responses [22]. This is critical for determining the efficacy of SARS-CoV-2 699 700 vaccines in this population. However, due to the small sample size and omission of this 701 group in various studies, the review was unable to highlight this. Adenovirus vaccine

31

702 vectors and HIV acquisition risk are also highlighted. Even though this outcome was included in the study protocol [24], we did find studies related to it. According to 703 preliminary research, adenovirus type 5 (Ad5) immune complexes activate the dendritic 704 705 cell-T cell axis, which may enhance HIV-1 replication in CD4 T cells [87, 88]. Additionally, Ad5-specific CD4 T cells may be more susceptible to HIV infection [88, 89]. 706 A participant-level meta-analysis of six randomized trials in which 224 participants 707 received recombinant adenovirus serotype-5 (rAd5)-vector preventive HIV-1 vaccines 708 and 179 participants received a placebo revealed an increased risk of HIV-1 infection by 709 the vaccine overall follow-up time, but no evidence of an increased risk of HIV-1 710 infection by DNA/rAd5 [90]. Due to the small sample size of most of the included trials, 711 vaccination with a rAd5 vector increased mucosal T cell activation, which remains a 712 713 central hypothesis to explain the potential enhancement of HIV acquisition in SARS-714 CoV-2 vaccines based on the rAd5 vector. In the future, large efficacy trials of such vaccines will be required. 715

Other study limitations were some data were taken from interim reports and the supplementary data provided with them. These documents had limited information in the summarized format and the individual patient data was not available, thus there is a possibility to miss some important aspects. The main limitations to this analysis are related with the intrinsic weaknesses of the included studies as shown in the risk of bias assessment (**Supplemental materials Table 2 & 3**). However, the results showed almost perfect inconsistency, indirectness, and imprecision.

723

724 **5.** Conclusion

32

725 According to our findings, PLWH had lower immunogenicity and antigenicity than HIVnegative people after the second dose of SARS-CoV-2 vaccines. However, the 726 reactogenicity was the same after the first and second doses of SARS-CoV-2 vaccines. 727 728 The antigenicity was lower among PLWH with CD4<500 cells/µl. In contrast, the immunogenicity was not different between PLWH with CD4<500 vs ≥500 cells/µl as well 729 730 as CD4 count <350 vs ≥350 cells/µl. In the same line, immunogenicity among PLWH with CD4 count <200 cells/µl should be considered in the context of a small sample 731 732 size.

SARS-CoV-2 vaccines tolerability after the first and second dose was not different between PLWH and HIV negatives. However, systemic reactions after the first and second doses of SARS-CoV-2 vaccines varied between studies depending on the type of vaccine. Protein subunit vaccine reported a lower risk of systemic reactions after the first SARS-CoV-2 vaccine among PLWH. In the same line, both mRNA and viral vector vaccines reported a lower risk of systemic reaction among PLWH.

Based on the above, we recommend an additional dose of SARS-CoV-2 vaccination to PLWH with CD4 count ≥200 cells/ μ l, low HIV viral loads, and on ART.

Our findings should be interpreted considering several study limitations, including the study's small sample size and lack of long-term assessment of SARS-CoV-2 immunogenicity as an ideal vaccine that should provide rapid, multifaceted, long-term protection. Large-scale prospective studies, including long-term antibody monitoring, are required in the future for PLWH. Furthermore, more research should be conducted to determine whether giving a third primary dose to PLWH with a CD4 count < 200

33

747 cells/l is unlikely to result in significant harms or disadvantages but may offer the 748 possibility of benefit.

749 **6. Abbreviations**

ACE2: angiotensin-converting enzyme 2; ART: Antiretroviral therapy; AU: BAU: BHIVA: 750 British HIV Association; CD4+ T: CD8+ T: COVID-19: coronavirus disease 2019; DNA: 751 752 Deoxyribonucleic acid; ELISA: enzyme-linked immunosorbent assay; FDA: Food and Drug Administration; GAVI: Global Alliance for Vaccines and Immunisation GRADE: 753 Grading of Recommendations, Assessment, Development, and Evaluation; HAART: 754 755 highly active antiretroviral therapy; HIV: Human Immunodeficiency virus; IgG 756 immunoglobin G; mRNA: messenger ribonucleic acid; rAd5: recombinant adenovirus type 5; RBD: SARS-CoV-2 Spike Protein; ROBIN-1: PLWH: people living with HIV; 757 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; 758 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VOC: variant(s) of 759 760 concern; WHO: World Health Organization

761 7. Footnotes

Authors' contributions: The project was initiated by JLT and PSN. JLT registered the review into Prospero and conducted an electronic search of various databases. The data extraction and risk of bias assessment were carried out by JLT and LMM in collaboration with PSN. JLT carried out a statistical analysis. JLT wrote the manuscript with the help of PSN and AM. The manuscript was reviewed and edited by JLT, PSN, LMM, and AM. The final version of the manuscript was approved by all authors.

- 768 **Funding:** The authors have not declared a specific grant from any funding agency in
- the public, commercial, or not-for-profit sectors for this research.
- 770 **Competing interests:** None declared.
- 771 Availability of data and materials: All relevant data for the study are included in the
- article or are available as supplemental materials.
- 773 Ethics approval and consent to participate: Not applicable.
- 774 **Consent for publication:** Not applicable.

775 8. References

- 1. UNAIDS. Global HIV & AIDS statistics Fact sheet, 2021.
- 777 <u>https://www.unaids.org/en/resources/fact-sheet</u>
- 2. Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR
- 779 Mayala BK, et al. Mapping HIV prevalence in sub-Saharan Africa between 2000
- and 2017. Nature 2019, 570(7760), pp.189-193.
- 3. Clinical features and prognostic factors of COVID-19 in people living with HIV
- hospitalized with suspected or confirmed SARS-CoV-2 infection, 2021.
- 783 https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-HIV-2021.1
- 4. Bertagnolio S et al. Clinical characteristics and prognostic factors in people living
- 785 with HIV hospitalized with COVID-19: Findings from the WHO Global Clinical
- 786 Platform. 11th IAS Conference on HIV Science, abstract PEBLB20, 2021.
- 787 https://theprogramme.ias2021.org/Abstract/Abstract/2498

788	5.	Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, et al. Epidemiology and
789		outcomes of COVID-19 in HIV-infected individuals: a systematic review and
790		meta-analysis. Scientific Reports 2021, 11(1): 1-12.
791	6.	Deeks SG and Phillips AN. HIV infection, antiretroviral treatment, ageing, and
792		non-AIDS-related morbidity. BMJ 2009; 338: a3172.
793	7.	Alrubayyi A, Gea-Mallorquí E, Touizer E, Hameiri-Bowen D, et al.
794		Characterization of humoral and SARS-CoV-2 specific T cell responses in
795		people living with HIV. bioRxiv 2021.
796		https://www.biorxiv.org/content/biorxiv/early/2021/02/16/2021.02.15.431215.full.p
797		df
798	8.	Moir S and Fauci AS (2017), B-cell responses to HIV infection. Immunol Rev
799		2017; 275 (1): 33-48.
800	9.	Pallikkuth S, et al. Impaired peripheral blood T-follicular helper cell function in
801		HIV-infected nonresponders to the 2009 H1N1/09 vaccine. Blood 2012; 120 (5):
802		985-93.
803	10	. Hoffmann M, Pantazis N, Martin GE, et al. Exhaustion of Activated CD8 T Cells
804		Predicts Disease Progression in Primary HIV-1 Infection. PLoS Pathog 2016; 12:
805		e1005661.
806	11	.Parmigiani A, Alcaide ML, Freguja R, Pallikkuth S, Frasca D, Fischl MA, Pahwa
807		S. Impaired antibody response to influenza vaccine in HIV-infected and
808		uninfected aging women is associated with immune activation and inflammation.
809		PLoS One. 2013;8(11): e79816.

810	12. Spinelli MA, Lynch KL, Yun C, Glidden DV, Peluso MJ, Henrich TJ, Gandhi M,
811	Brown LB. SARS-CoV-2 seroprevalence, and IgG concentration and
812	pseudovirus neutralising antibody titres after infection, compared by HIV status:
813	a matched case-control observational study. Lancet HIV. 2021;8(6): e334-e341.
814	13. Choi EM. COVID-19 vaccines for low- and middle-income countries. Trans R
815	Soc Trop Med Hyg. 2021;115(5):447-456.
816	14. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of 678
817	Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015;
818	373: 795–807.
819	15. SPARTAC Trial Investigators, Fidler S, Porter K, et al. Short-course antiretroviral
820	681 therapy in primary HIV infection. N Engl J Med 2013; 368: 207–17.
821	16. Frater J, Ewer K, Ogbe A, Pace M. Adele S, Adland E, et al. Safety and
822	immunogenicity of the ChAdox1 nCoV-19 (AZD1222) vaccine against SARS-
823	CoV-2 in HIV infection, 2021.
824	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3829931
825	17. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity, and mortality
826	among patients with advanced human immunodeficiency virus infection. HIV
827	Outpatient Study Investigators. N Engl J Med 1998; 338: 853–60.
828	18. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression
829	on HIV691 specific CD8+ T cells leads to reversible immune dysfunction. Nat
830	Med 2006; 12: 1198-202
831	19. Paiardini M and Müller-Trutwin M. HIV-associated chronic immune activation.
832	Immunol Rev 2013; 254: 78–101.

833	20. Riou C, du Bruyn E, Stek C, Daroowala R, Goliath RT, Abrahams F, Said-Hartley
834	Q, Allwood BW, Hsiao NY, Wilkinson KA, Arlehamn CSL, Sette A, Wasserman
835	S, Wilkinson RJ; HIATUS consortium. Relationship of SARS-CoV-2-specific CD4
836	response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.
837	J Clin Invest. 2021;131(12): e149125.
838	21.WHO. Coronavirus disease (COVID-19): COVID-19 vaccines and people living
839	with HIV, 2021. https://www.who.int/news-room/q-a-detail/coronavirus-disease-
840	(covid-19)-covid-19-vaccines-and-people-living-with-hiv
841	22. BHIVA. Recommendations from the Joint Committee on Vaccination and
842	Immunisation (JCVI) on a third COVID vaccine dose. Guidance for People Living
843	with HIV
844	23. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. Updating
845	guidance for reporting systematic reviews: development of the PRISMA 2020
846	statement. Journal of Clinical Epidemiology 2021; 134: 103-112.
847	24. Nyasulu PS, Tamuzi JL, Ayele B. A systematic review and meta-analysis of
848	COVID-19 vaccines safety, tolerability and efficacy among HIV-infected patients.
849	PROSPERO 2021 CRD42021228863.
850	https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021228863
851	25. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb).
852	2012;22(3):276-82.
853	26. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J,
854	Schulz KF, Weeks L, Sterne JA; Cochrane Bias Methods Group; Cochrane

855	Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk
856	of bias in randomised trials. BMJ. 2011;343: d5928.
857	27. Thomson H, Craig P, Hilton-Boon M, Campbell M, Katikireddi SV. Applying the
858	ROBINS-I tool to natural experiments: an example from public health. Syst Rev.
859	2018;7(1):15.
860	28. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-
861	CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ
862	Vaccines. 2021;6(1):28.
863	29. Negahdaripour M. COVID-19 Vaccine Global Access Is an Urgency. Iran. J.
864	Med. Sci. 2021;46(2):79–80.
865	30. Negahdaripour M. Structural vaccinology considerations for in silico designing of
866	a multi-epitope vaccine. Infect. Genet. Evol. 2018; 58:96–109.
867	31.He Q, Mao Q, Zhang J, Bian L, Gao F, Wang J, Xu M, Liang Z. COVID-19
868	Vaccines: Current Understanding on Immunogenicity, Safety, and Further
869	Considerations. Front Immunol. 2021; 12:669339.
870	32. Keech C. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein
871	Nanoparticle Vaccine. N. Engl. J. Med. 2020;383(24):2320-2332.
872	33. Wang Q., Berger N.A., Xu R. Analyses of risk, racial disparity, and outcomes
873	among US patients with cancer and COVID-19 infection. JAMA Oncol.
874	2021;7(2):220–227.
875	34. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B,
876	Hotez PJ. Roadmap to developing a recombinant coronavirus S protein receptor-

877	binding domain vaccine for severe acute respiratory syndrome. Expert Rev
878	Vaccines. 2012;11(12):1405-13.
879	35. Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the
880	development of SARS-CoV-2 vaccines. Int J Biol Sci. 2021; 17(1):8-19.
881	36. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon
882	M, Meade P, Mendu DR, Muellers K, Stadlbauer D, Stone K, Strohmeier S,
883	Simon V, Aberg J, Reich DL, Krammer F, Cordon-Cardo C. Robust neutralizing
884	antibodies to SARS-CoV-2 infection persist for months. Science.
885	2020;370(6521):1227-1230.
886	37. Dogan M, Kozhaya L, Placek L, Gunter C, Yigit M, Hardy R, Plassmeyer M,
887	Coatney P, Lillard K, Bukhari Z, Kleinberg M, Hayes C, Arditi M, Klapper E,
888	Merin N, Liang BT, Gupta R, Alpan O, Unutmaz D. SARS-CoV-2 specific
889	antibody and neutralization assays reveal the wide range of the humoral immune
890	response to virus. Commun Biol. 2021;4(1):129.
891	38. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager
892	(RevMan) [Computer program] Version Version 5.3. Copenhagen: The Nordic
893	Cochrane Centre, The Cochrane Collaboration; 2014.
894	39. ProMeta 3 [Computer program] https://idostatistics.com/prometa-3-available/
895	40. McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A; Depression Screening
896	Data (DEPRESSD) Collaboration. Estimating the sample mean and standard
897	deviation from commonly reported quantiles in meta-analysis. Stat Methods Med
898	Res. 2020:962280219889080.

899	41. Meschi S, Matusali G, Colavita F, Lapa D, Bordi L, Puro V, Leoni BD, Galli C,
900	Capobianchi MR, Castilletti C; INMI Covid-19 laboratory and investigation team.
901	Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine.
902	Clin Chem Lab Med. 2021;59(12):2010-2018.
903	42. Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for
904	statistical and clinical significance in systematic reviews with meta-analytic
905	methods. BMC Med Res Methodol. 2014; 14:120.
906	43. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, Moe-Byrne T,
907	Higgins JP, Sowden A, Stewart G. A checklist designed to aid consistency and
908	reproducibility of GRADE assessments: development and pilot validation. Syst
909	Rev. 2014; 3:82.
910	44. Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L,
911	Huppert A, Mor O, Goldstein M, Sapir E, Hod T, Cohen C, Lustig Y, Rahav G.
912	Immunogenicity, and safety of the BNT162b2 mRNA Covid-19 vaccine in people
913	living with HIV-1. Clin Microbiol Infect. 2021: S1198-743X (21)00423-7.
914	45. Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, Padayachee SD,
915	Dheda K, Barnabas SL, Bhorat QE, Briner C, Aley PK, Bhikha S, Hermanus T,
916	Horne E, Jose A, Kgagudi P, Lambe T, Masenya M, Masilela M, Mkhize N,
917	Moultrie A, Mukendi CK, Moyo-Gwete T, Nana AJ, Nzimande A, Patel F, Rhead
918	S, Taoushanis C, Thombrayil A, van Eck S, Voysey M, Villafana TL, Vekemans
919	J, Gilbert SC, Pollard AJ, Moore PL, Kwatra G; Wits VIDA COVID team. Safety
920	and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against
921	SARS-CoV-2 in people living with and without HIV in South Africa: an interim

922	analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
923	Lancet HIV. 2021 Aug 17: S2352-3018(21)00157-0.
924	46. Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U,
925	Masilela MSL, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N,
926	Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de
927	Oliveira T, Lombard Koen A, Lombaard JJ, Mngqibisa R, Bhorat AE, Benadé G,
928	Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen-Jose
929	A, Foulkes S, Ahmed K, Thombrayil A, Fries L, Cloney-Clark S, Zhu M, Bennett
930	C, Albert G, Faust E, Plested JS, Robertson A, Neal S, Cho I, Glenn GM,
931	Dubovsky F, Madhi SA; 2019nCoV-501 Study Group. Efficacy of NVX-CoV2373
932	Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med.
933	2021;384(20):1899-1909.
934	47. Nault L, Marchitto L, Goyette G, Tremblay-Sher D, Fortin C, Martel-Laferrière V,
935	Trottier B, Richard J, Durand M, Kaufmann D, Finzi A, Tremblay C. Covid-19
936	vaccine immunogenicity in people living with HIV-1. bioRxiv 2021.08.13.456258;
937	doi: https://doi.org/10.1101/2021.08.13.456258
938	48. Haidar G, Agha M, Lukanski A, Linstrum K, Troyan R, Bilderback A,
939	Rothenberger S, McMahon DK, Crandall M, Enick PN, Sobolewksi M.
940	Immunogenicity of COVID-19 vaccination in immunocompromised patients: an
941	observational, prospective cohort study interim analysis.
942	https://doi.org/10.1101/2021.06.28.21259576
943	49. Janssen. Use of the Janssen COVID-19 Vaccine in Patients Living with Human
944	Immunodeficiency Virus (HIV), 2021. https://www.janssenmd.com/janssen-

945	covid19-vaccine/special-populations/hiv/use-of-the-janssen-covid19-vaccine-in-

- 946 patients-living-with-human-immunodeficiency-virus-hiv
- 50. Moderna COVID-19 Vaccine. Vaccines and Related Biological Products Advisory
- 948 Committee December 17, 2020, Meeting Briefing Document FDA.
- 949 https://www.fda.gov/media/144434/download
- 51. Brumme ZL, Mwimanzi F, Lapointe HR, Cheung P, Sang Y, Duncan MC, Yaseen
- 951 F, Agafitei O, Ennis S, Ng K, Basra S, Lim LY, Kalikawe R, Speckmaier S,
- Moran-Garcia N, Young L, Ali H, Ganase B, Umviligihozo G, Omondi FH,
- Atkinson K, Sudderuddin H, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C,
- Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Romney
- MG, Barrios R, Guillemi S, Brumme CJ, Pantophlet R, Montaner JSG, Niikura M,
- 956 Harris M, Hull M, Brockman MA. Humoral immune responses to COVID-19
- vaccination in people living with HIV receiving suppressive antiretroviral therapy.
- 958 medRxiv [Preprint]. 2021:2021.10.03.21264320. doi:
- 959 10.1101/2021.10.03.21264320.
- 52. Zou S, Wu M, Ming F, Wu S, Guo W, Marly G, Zeng M, Sun C, Zhang J, Tang
- 961 W, Liang K. Immune Response and Safety to Inactivated COVID-19 Vaccine: A
- Comparison Between People Living with HIV and HIV-naïve Individuals, 2021.
 Available at SSRN 3901795.
- 53. Ogbe A, Pace M, Bittaye M, Tipoe T, Adele S, Alagaratnam J, Aley PK, Ansari
- 965 MA, Bara A, Broadhead S, Brown A. Durability of ChAdOx1 nCov-19 (AZD1222)
- vaccination in people living with HIV-responses to SARS-CoV-2, variants of

967	concern and circulating coronaviruses, 2021. Doi:
968	https://doi.org/10.1101/2021.09.28.21264207
969	54. Feng Y, Zhang Y, He Z, Huang H, Tian X, Wang G, Chen D, Ren Y, Jia L, Wang
970	W, Wu J. Immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine in
971	people living with HIV-1, 2021.
972	https://www.medrxiv.org/content/medrxiv/early/2021/10/15/2021.09.14.21263556
973	.full.pdf
974	55. Spinelli M, Peluso MJ, Lynch KL, Yun CA, Glidden DV, Henrich TJ, Deeks S,
975	Gandhi M. Post-Mrna Vaccination SARS-CoV-2 IGG Concentrations and
976	Surrogate Virus Neutralization Response Compared by HIV Status and Type of
977	Vaccine: A Matched Case-Control Observational Study, 2021. Available at
978	SSRN 3909785.
979	56. Netto LC, Ibrahim KY, Picone CM, da Silva Alves AP, Aniceto EV, Santiago MR,
980	Parmejani PD, Aikawa NE, Medeiros-Ribeiro AC, Pasoto SG, Yuki EF. Safety
981	and Immunogenicity of CoronaVac in People Living with HIV, 2021.
982	https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3928503
983	57. Khan K, Lustig G, Bernstein M, Archary D, Cele S, Karim F, Smith M, Ganga Y,
984	Jule Z, Reedoy K, Miya Y. Immunogenicity of the Ad26. CoV2. S vaccine in
985	people living with HIV, 2021. doi: https://doi.org/10.1101/2021.10.08.21264519
986	58. Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, Lanini S, De
987	Pascale L, Matusali G, Mariotti D, Lepri AC. Humoral and Cellular Immune
988	Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living
989	with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current

44

990 CD4 T-Lymphocyte Count, 2021.

- 991 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3929972
- 59. Cai SH, Liao G, Yu T, Gao Q, Zou L, Zhang H, Xu X, Chen J, Lu A, Wu Y, Li B.
- 993 Immunogenicity and Safety of Inactivated SARS-CoV-2 Vaccine in People Living
- 994 with HIV: A Cross-Sectional Study, 2021. Available at SSRN 3912536
- 995 60. Jedicke N, Stankov MV, Cossmann A, Dopfer-Jablonka A, Knuth C, Ahrenstorf
- 996 G, Ramos GM, Behrens GMN. Humoral immune response following prime and
- boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
- 998 HIV Med. 2021 Nov 2. doi: 10.1111/hiv.13202.
- 999 61. Huang X, Yan Y, Su B, Xiao D, Yu M, Jin X, Duan J, Zhang X, Zheng S, Fang Y,
- 1000 Tang W. Comparing Immune Responses to Inactivated Vaccines Against SARS-
- 1001 CoV-2 Between People Living with HIV and HIV-Negative Individuals: A Cross-
- 1002 Sectional Study in China.
- 1003 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3941042
- 1004 62. Mazus A, Gushchin VA, Tsyganova EV, Ogarkova DA, Adgamov RR,
- 1005 Shcheblyakov DV, Glukhoedova NV, Zhilenkova A, Kolotii AG, Zaitsev RD,
- 1006 Logunov DY. Sputnik V Protection from COVID-19 of HIV-Infected Individuals
- 1007 Under Art. Available at SSRN 3949413. 2021 Oct 25.
- 1008 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3949413
- 1009 63. Lv Z, Li Q, Feng Z, Zheng X, Yang H, Gu Q, Ying S, Qi Y, Li X, Wu R, Wu Z.
- 1010 Inactivated SARS-CoV-2 Vaccines Elicit Immunogenicity and T-cell Responses
- in People Living with HIV. International Immunopharmacology. 2021; 18:108383.

	1012	64. Bergman P	, Blennow O,	Hansson L,	Mielke S,	Nowak P,	Chen P,	Söderdahl G,
--	------	---------------	--------------	------------	-----------	----------	---------	--------------

- 1013 Österborg A, Smith CIE, Wullimann D, Vesterbacka J, Lindgren G, Blixt L,
- 1014 Friman G, Wahren-Borgström E, Nordlander A, Gomez AC, Akber M, Valentini
- D, Norlin AC, Thalme A, Bogdanovic G, Muschiol S, Nilsson P, Hober S, Loré K,
- 1016 Chen MS, Buggert M, Ljunggren HG, Ljungman P, Aleman S; COVAXID-
- 1017 collaborator group (shown separately). Safety and efficacy of the mRNA
- 1018 BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised
- 1019 patients and healthy controls in a prospective open-label clinical trial.
- 1020 EBioMedicine. 2021; 74:103705.
- 1021 65. Cheng SH, Lien CE, Hsieh SM, Cheng CY, Liu WD, Lo CL, Ko WC, Chen YH,
- Huang CT, Chang HT, Hwang SJ. Safety and Immunogenicity of SARS-CoV-2
- 1023 S-2P Protein Vaccine MVC-COV1901 in People Living with HIV, 2021.
- 1024 https://www.medrxiv.org/content/10.1101/2021.12.08.21267439v1.full.pdf
- 1025 66. Noe S, Ochana N, Wiese C, Schabaz F, Von Krosigk A, Heldwein S, Rasshofer
- 1026 R, Wolf E, Jonsson-Oldenbuettel C. Humoral response to SARS-CoV-2 vaccines
- in people living with HIV. Infection. 2021:1–7.
- 1028 67. Xiao Y, Wu S, Marly G, Ming F, Wu M, et al. People Living with HIV Easily Lose
- 1029 Their Immune Response to SARS-CoV-2: Result from a Cohort of COVID-19
- 1030 Cases in Wuhan, China 2021. http://dx.doi.org/10.2139/ssrn.3774187
- 1031 68. Whitaker H, Tsang R, Byford R, Andrews N, Sherlock J, Pillai S et al. Pfizer-
- 1032 BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and
- immune response among individuals in clinical risk groups. 2021.

- 1034 https://khub.net/documents/135939561/430986542/RCGP+VE+riskgroups+pape
- 1035 r.pdf/a6b54cd9-419d-9b63-e2bf-5dc796f5a91f
- 1036 69. CDC. COVID-19 Vaccines for Moderately to Severely Immunocompromised
- 1037 People, 2021. https://www.cdc.gov/coronavirus/2019-
- 1038 ncov/vaccines/recommendations/immuno.html
- 1039 70. FDA. Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the
- 1040 Use of a Booster Dose for COVID-19 Vaccines, 2021.
- 1041 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-
- 1042 update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines
- 1043 71. Roifman CM and Vong L. COVID-19 post-vaccination recommendations in
- 1044 primary immunodeficiency, 2021.
- 1045 https://lymphosign.com/doi/abs/10.14785/lymphosign-2021-0023
- 1046 72. BHIVA. SARS-CoV-2 vaccine advice for adults living with HIV: British HIV
- 1047 Association (BHIVA) & Terrence Higgins Trust (THT) guidance, 2021.
- 1048 https://www.bhiva.org/SARS-CoV-2-vaccine-advice-for-adults-living-with-HIV-
- 1049 update
- 1050 73. WHO. Interim statement on COVID-19 vaccine booster doses, 2021.
- 1051 https://www.who.int/news/item/10-08-2021-interim-statement-on-covid-19-
- 1052 vaccine-booster-doses
- 1053 74. Biggar RJ, Goedert JJ and Hoofnagle J., 1987. Accelerated loss of antibody to
- 1054 hepatitis B surface antigen among immunodeficient homosexual men infected
- 1055 with HIV. The New England journal of medicine 1987; 316(10): 630-631.

1056	75. Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, Kenney T, et al. Poor
1057	immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected
1058	individuals. Aids 2010, 24(14): 2187-2192.
1059	76. Kernéis S, Launay O, Turbelin C, Batteux F, Hanslik T, et al. Long-term immune
1060	responses to vaccination in HIV-infected patients: a systematic review and meta-
1061	analysis. Clinical infectious diseases 2014, 58(8), pp.1130-1139.
1062	77. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine
1063	injections augments anti-HBs response rate in HIV-infected patients. Effects on
1064	HIV-1 viral load. Vaccine 2000; 18: 1161–5.
1065	78. Gong C, Song X, Li X, Lu L, Li T. Immunological Changes after COVID-19
1066	Vaccination in an HIV-Positive Patient. Int J Infect Dis. 2021: S1201-
1067	9712(21)00667-6.
1068	79. Bozzi G, Lombardi A, Ludovisi S, Muscatello A, Manganaro L, Cattaneo D, Gori
1069	A, Bandera A. Transient increase in plasma HIV RNA after COVID-19
1070	vaccination with mRNA-1272. Int J Infect Dis. 2021; 113:125-126.
1071	80. BHIVA. UPDATE: Intensive Care Society (ICS) and British HIV Association
1072	(BHIVA) statement on considerations for critical care for people with HIV during
1073	COVID-19, 2020. https://www.bhiva.org/updated-ICS-BHIVA-statement-on-
1074	considerations-for-critical-care-for-people-with-HIV-during-COVID-19
1075	81. Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, et
1076	al. An observational cohort study on the incidence of SARS-CoV-2 infection and
1077	B.1.1.7 variant infection in healthcare workers by antibody and vaccination status

48

1078 medRxiv 2021 [Internet]. Available from: http://medrxiv.org/content/	'early/
---	---------

1079 2021/03/12/2021.03.09.21253218.

- 1080 82. Huang X, Yu M, Fu G, Lan G, Li L, Yang J, Qiao Y, Zhao J, Qian HZ, Zhang X,
- Liu X, Jin X, Chen G, Jiang H, Tang W, Wang Z, Xu J. Willingness to Receive
- 1082 COVID-19 Vaccination Among People Living with HIV and AIDS in China:
- 1083 Nationwide Cross-sectional Online Survey. JMIR Public Health Surveill.
- 1084 2021;7(10): e31125.
- 1085 83. Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic
- 1086 Review of Vaccine Acceptance Rates. Vaccines (Basel). 2021 Feb 16;9(2):160.

1087 doi: 10.3390/vaccines9020160. PMID: 33669441; PMCID: PMC7920465.

- 1088 84. Kaida A, Brotto LA, Murray MC, Côté HC, Albert AY, Nicholson V, Gormley R,
- 1089 Gordon S, Booth A, Smith LW, Baaske A. Intention to receive a COVID-19
- 1090 vaccine by HIV status among a population-based sample of women and gender
- 1091 diverse individuals in British Columbia, Canada. medRxiv. 2021 Jan 1. doi:
- 1092 https://doi.org/10.1101/2021.08.19.21262249
- 1093 85. Ekstrand ML, Heylen E, Gandhi M, Steward WT, Pereira M, Srinivasan K.
- 1094 COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for
- 1095 Vaccination Campaigns. J Acquir Immune Defic Syndr. 2021;88(5):421-425.
- 1096 86. Vallée A, Fourn E, Majerholc C, Touche P, Zucman D. COVID-19 Vaccine
- 1097 Hesitancy among French People Living with HIV. Vaccines (Basel). 2021 Mar
- 1098 24;9(4):302.

49

1099	87. Perreau M, Pantaleo	G, Kremer EJ. Activation o	f a dendritic cell-T cell axis by
------	-------------------------	----------------------------	-----------------------------------

- 1100 Ad5 immune complexes creates an improved environment for replication of HIV
- in T cells. J Exp Med 2008; 205: 2717–25.
- 1102 88. Buchbinder SP, McElrath MJ, Dieffenbach C, Corey L. Use of adenovirus type-5

vectored vaccines: a cautionary tale. Lancet. 2020;396(10260): e68-e69.

- 1104 89. Auclair S, Liu F, Niu Q, et al. Distinct susceptibility of HIV vaccine vector induced
- 1105 CD4 T cells to HIV infection. PLoS Pathog 2018; 14: e1006888.
- 1106 90. Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z,
- 1107 Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A,
- 1108 McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG,
- 1109 Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB. Effect of rAd5-
- 1110 Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level
- 1111 Meta-Analysis of Randomized Trials. PLoS One. 2015;10(9): e0136626.



Figure 1: Flow diagram of COVID-19 vaccines safety, tolerability, and efficacy among HIV-infected patients



Distribution of twenty-three included studies in different countries

Figure 2: Distribution of twenty-three included studies in different countries



Figure 3: Forest plot analysis of the overall risk ratio RBD antibody responses after the

first dose of SARS-CoV-2 vaccines among PLWH and HIV-negative people.

	PLW	н	HIV negative p	people		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.2.1 mRNA vaccines							
Antinori 2021	155	160	168	168	10.9%	0.97 [0.94, 1.00]	1
Bergman 2021	89	90	90	90	10.8%	0.99 [0.96, 1.02]	1
Haidar 2021	35	37	105	107	6.9%	0.96 [0.89, 1.05]	Ţ
Levy 2021 Nout 2021	139	141	269	272	11.3%	1.00 [0.97, 1.02]	1
Nauli 2021 Phinolli 2021	100	100	19	100	5.1% 6.7%	0.99[0.89,1.11]	_
Subtotal (95% CI)	00	634	55	757	51.7 %	0.98 [0.96, 1.00]	
Total events	606		746				
Heterogeneity: Tau ² =	0.00; Chi	z = 6.2	1, df = 5 (P = 0.2	29); I ² = 2	0%		
Test for overall effect:	Z=1.88 (P = 0.0	16)				
1.2.2 Viral vector vac	cines						
Frater 2021	29	43	17	28	0.8%	1.11 [0.77, 1.60]	
Janssen 2021	316	461	356	493	6.9%	0.95 [0.87, 1.03]	-
Khan 2021	23	26	73	73	3.6%	0.88 [0.76, 1.01]	
Madhi 2021	28	32	22	23	3.2%	0.91 [0.78, 1.07]	
Subtotal (95% CI)		562		617	14.4%	0.93 [0.88, 1.00]	•
Total events	396		468				
Heterogeneity: Tau ² =	0.00; Chi	² = 2.0	4, df = 3 (P = 0.5	56); I ^z = 0	%		
l'est for overall effect.	Z = 2.09 (Ρ= 0.0	14)				
1.2.3 Inactivated vac	cines						
Cai 2021	83	143	38	50	2.1%	0.76 [0.62, 0.94]	
Huang 2021	120	129	52	53	8.6%	0.95 [0.89, 1.01]	*
Netto 2021	185	204	265	274	9.5%	0.94 [0.89, 0.98]	•
Zou 2021 Subtotal (95% CI)	19	46 522	24	38	0.6% 20.7%	0.65 (0.43, 1.00) 0.90 (0.81, 0.99)	•
Total events	407		379				•
Heterogeneity: Tau ² =	0.01; Chi	² = 11.	43, df = 3 (P = 0	.010); i ² :	= 74%		
Test for overall effect:	Z= 2.13 (P = 0.0)3)				
1.2.4 Protein subunit	vaccines						
Cheng 2021	58	58	3289	3295	11.3%	0.99 (0.97, 1.02)	
Shinde 2021	46	109	1368	2684	1.9%	0.83 [0.66, 1.03]	
Subtotal (95% CI)		167		5979	13.1%	0.91 [0.42, 1.98]	
Total events	104		4657				
Heterogeneity: Tau ² =	0.31; Chi	² = 48	49, df = 1 (P ≺ 0	.00001);	I ^z = 98%		
Test for overall effect:	Z=0.24 (P = 0.8	31)				
Total (95% CI)		1885		7768	100.0%	0.95 [0.92, 0.99]	•
Total events	1513		6250				
Heterogeneity: Tau² =	0.00; Chi	= 68.3	35, df = 15 (P <	0.00001)); l² = 78%	6	
Test for overall effect:	Z = 2.75 (P = 0.0	106)				PLWH HIV negative people
Test for subgroup diff	erences: (Chi ^z = :	5.11, df = 3 (P =	0.16), I ^z	= 41.3%		

Figure 4: Forest plot analysis of the overall risk ratio RBD antibody responses after the second dose of SARS-CoV-2 vaccines among PLWH and HIV-negative people.



Figure 5: Forest plot of mean difference IgG antibody level (BAU/mI) after the second

dose of SARS-CoV-2 vaccines

	1	PLWH		HIV ne	egative peo	ple	Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	IV, Random, 95% Cl		IV, Random, 95% Cl
1.10.1 mRNA vaccine	s								
Antinori 2021	1,563.83	1,250.53	160	3,008.8	2,512.01	168	-1444.97 [-1871.39, -1018.55]	4	
Haidar 2021	14.04	16.83	37	16.22	16.25	107	-2.18 [-8.42, 4.06]	_	
Jedicke 2021	45.54	48.05	50	71.24	13.67	41	-25.70 [-39.66, -11.74]	•	
Levy 2021	5.2	0.51	141	6	0.43	272	-0.80 [-0.90, -0.70]		E I
Spinelli 2021	205.73	330.25	100	291.27	493.12	100	-85.54 [-201.86, 30.78]	•	
1.10.2 Viral vector va	ccines								
Frater 2021	164.84	132.83	49	165.92	131.96	28	-1.08 [-62.50, 60.34]	•	
Madhi 2021	502.57	524.18	32	443.23	307.48	23	59.34 [-161.51, 280.19]	•	
1.10.3 Inactivated va	ccines								
Feng 2021	24.54	6.5	42	29	5.93	28	-4.46 [-7.41, -1.51]		
Huang 2021	1.23	1.02	129	2.22	2.35	53	-0.99 [-1.65, -0.33]		+
Netto 2021	10.21	11.17	215	12.71	8.25	296	-2.50 [-4.26, -0.74]		— + —
Zou 2021	4.58	1.92	46	26.13	26.71	38	-21.55 [-30.06, -13.04]	•	
1.10.4 Mixed doses/n	nRNA and v	/iral vector	vaccii	ies					
Brumme 2021	34.42	7.54	96	36.65	6.9	151	-2.23 [-4.10, -0.36]		
Ogbe 2021	105.26	7.44	54	147.73	38.65	60	-42.47 [-52.45, -32.49]	•	
								I	<u> </u>
								-10	-5 U 5 10 PLWH HV pagative people
									FLWH HIV negative people

Figure 6: Forest plot of mean difference IgG antibody level (BAU/mI) after the second of

SARS-CoV-2 vaccines

	HIV+(Vacci	nated)	HIV+(Unvac	cinated)		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.13.1 mRNA vaccin	es						
Moderna 2021	1	90	1	86	0.7%	0.96 [0.06, 15.04]	·
Subtotal (95% CI)		90		86	0.7%	0.96 [0.06, 15.04]	
Total events	1		1				
Heterogeneity: Not a	oplicable						
Test for overall effect	Z = 0.03 (P =	0.97)					
1.13.2 Viral vector va	accines						
Janssen 2021	2	461	4	493	1.8%	0.53 [0.10, 2.91]	
Shinde 2021	2	109	4	102	1.9%	0.47 [0.09, 2.50]	• <u> </u>
Vladimir 2021	71	2543	1354	16606	95.6%	0.34 [0.27, 0.43]	
Subtotal (95% CI)		3113		17201	99.3%	0.35 [0.28, 0.44]	◆
Total events	75		1362				
Heterogeneity: Tau ² =	= 0.00; Chi = (D.39, df=	2 (P = 0.82); I	l²=0%			
Test for overall effect	Z=8.99 (P ≤	0.00001)					
							•
Total (95% CI)		3203		17287	100.0%	0.35 [0.28, 0.44]	•
Total events	76		1363				
Heterogeneity: Tau ² =	= 0.00; Chi ² = (0.90, df =	3 (P = 0.82); I	I ² = 0%			
Test for overall effect	Z=8.96 (P ≤	0.00001)					HIV+(Vaccinated) HIV+(Unvaccinated)
Test for subgroup dif	ferences: Chi ^a	^e = 0.51, c	f = 1 (P = 0.4)	7), I² = 0%			The (eacemated) The (Offederinated)

Figure 7: Meta-analysis of SARS-CoV-2 vaccines effectiveness: vaccinated vs

unvaccinated PLWH.

	HIV+(Vaccir	nated)	HIV+(Unvacc	inated)		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.14.1 CD4 count<35	0 cells/µl						
Vladimir 2021 Subtatal (05%, CD	11	231	352	2997	25.9%	0.41 [0.23, 0.73]	
Subtotal (95% CI)		231		2997	25.9%	0.41[0.25, 0.75]	
i otal events	11		352				
Heterogeneity: Not ap	oplicable						
Test for overall effect:	Z = 3.02 (P =	0.002)					
1.14.2 CD4 count>=3	50 cells/µl						
Vladimir 2021	51	1967	779	8352	74.1%	0.28 [0.21, 0.37]	
Subtotal (95% CI)		1967		8352	74.1%	0.28 [0.21, 0.37]	◆
Total events	51		779				
Heterogeneity: Not ap	plicable						
Test for overall effect:	$Z=8.99$ (P \leq	0.00001))				
Total (05% CI)		2109		113/0	100.0%	0 34 [0 22 0 42]	
Total (35 % Cl)		2150		11545	100.070	0.51[0.22, 0.42]	•
Total events	62		1131				
Heterogeneity: Tau² =	: 0.02; Chi² = 1	.30, df=	1 (P = 0.25); I ²	= 23%			
Test for overall effect:	Z = 7.15 (P <	0.00001))				HIV+(Vaccinated) HIV+(Unvaccinated)
Test for subaroup diff	ferences: Chi ^z	= 1.30, c	#f = 1 (P = 0.25), I ² = 23.2	2%		The (encontaced) The (Onvacentated)

Figure 8: Meta-analysis of SARS-CoV-2 vaccines effectiveness based on CD4 count

	PLW	Ή	HIV negative pe	eople		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.3.1 mRNA vaccines	5						
Antinori 2021	133	153	72	73	17.9%	0.88 [0.82, 0.94]	•
Jedicke 2021	47	52	41	41	15.3%	0.91 [0.82, 1.00]	-
Spinelli 2021	76	100	88	100	12.5%	0.86 [0.76, 0.99]	
Subtotal (95% CI)		305		214	45.7%	0.89 [0.84, 0.93]	•
Total events	256		201				
Heterogeneity: Tau ² =	0.00; Ch	i² = 0.41	6, df = 2 (P = 0.80	0); I ² = 0	1%		
Test for overall effect:	Z = 4.67	(P < 0.0	10001)				
1.3.2 Inactivated vac	cines						
Cai 2021	65	67	19	20	14.4%	1.02 [0.92, 1.14]	+
Feng 2021	32	42	21	28	5.4%	1.02 [0.77, 1.33]	
Huang 2021	92	129	52	53	13.8%	0.73 [0.65, 0.82]	-
Netto 2021	143	202	229	274	14.9%	0.85 [0.76, 0.94]	+
Zhengchao 2021	19	24	21	24	5.9%	0.90 [0.70, 1.17]	
Subtotal (95% CI)		464		399	54.3%	0.88 [0.77, 1.02]	•
Total events	351		342				
Heterogeneity: Tau² =	0.02; Ch	i² = 19.I	69, df = 4 (P = 0.0	0006); P	²= 80%		
Test for overall effect:	Z = 1.65	(P = 0.1	0)				
Total (95% CI)		769		613	100.0 %	0.88 [0.82, 0.95]	•
Total events	607		543				
Heterogeneity: Tau ² =	0.01; Ch	i² = 20.1	62, df = 7 (P = 0.0	004); I² :	= 66%		
Test for overall effect:	Z = 3.40	(P = 0.0	1007)				PLWH HIV negative people
Test for subgroup diff	erences:	Chi² = I	0.00, df = 1 (P = 0),99), I²	= 0%		· Erni · int hogento poopio

Figure 9: Pooled results of SARS-CoV-2 vaccines neutralizing antibodies response after

the second dose

Study of Subgroup	PLW	H	HIV negative p	eople	Moight	Risk Ratio	Risk Ratio
1.4.1 mRNA vaccines	Events	Total	Events	Total	vveigni	M-H, Random, 95% CI	M-H, Kandom, 95% Ci
Levy 2021 Subtotal (95% CI)	54	133 133	102	399 399	22.2% 22.2 %	1.59 [1.22, 2.07] 1.59 [1.22, 2.07]	→
Total events Heterogeneity: Not ap	54 plicable	~ ~ ~ ~	102				
l est for overall effect:	Z = 3.42	(P = 0.0	JUU6)				
1.4.2 Viral vector vac	cines						
Frater 2021 Subtotal (95% CI)	40	53 53	44	50 50	24.0% 24.0 %	0.86 [0.71, 1.03] 0.86 [0.71, 1.03]	•
Total events Heterogeneity: Not ap	40 plicable		44				
Test for overall effect:	Z = 1.63	(P = 0.1	0)				
1.4.3 Inactivated vac	ines						
Netto 2021	23	189	71	296	17.8%	0.51 [0.33, 0.78]	_
Zou 2021	14	46	11	38	12.6%	1.05 [0.54, 2.04]	
Subtotal (95% CI)		235		334	30.4%	0.70 [0.34, 1.43]	
Total events	37		82				
Heterogeneity: Tau ² =	0.19; Ch	i≊ = 3.3 /¤ = 0.3	1, df = 1 (P = 0.0	I7); I² = 7	0%		
restior overall ellect.	2 - 0.90	(F = 0.3	55)				
1.4.4 Protein subunit	vaccines	6					
Shinde 2021 Subtotal (95% CI)	70	150 150	137	334 334	23.4% 23. 4%	1.14 [0.92, 1.41] 1.14 [0.92, 1.41]	
Total events	70		137				
Heterogeneity: Not ap	plicable	/n = 0 '					
restior overall ellect.	Z = 1.10	(F = 0.4	24)				
Total (95% CI)		571		1117	100.0%	0.98 [0.71, 1.36]	•
Total events	201		365				
Heterogeneity: Tau ² =	0.11; Ch	i ^z = 25.	16, df = 4 (P ≺ 0.	.0001); P	²= 84%		
Test for overall effect:	Z = 0.11	(P = 0.9	91) 45 70 46 0.00			~	PLWH HIV negative people
lest for subgroup diff	erences:	Chi*=	15.72, df = 3 (P :	= 0.001),	, if = 80.9	%	

Figure 10: Forest plot analysis compared the overall risk ratio of local reactions after

the first dose of SARS-CoV-2 vaccines among PLWH and HIV negatives.



Figure 11: Forest plot of systemic reactions after the first dose of SARS-CoV-2 vaccines: PLWH vs HIV negative participants

Study of Subgroup	PLW Events	H Total	HIV negative p	eople Total	Woight	Risk Ratio	Risk Ratio
1.5.1 mPNA vaccinos	Events	Total	Events	TOLA	weight	M-H, Kanuom, 95% Ci	M-H, Kandom, 95% Ci
Levy 2021 Subtotal (95% CI)	, 31	121 121	65	272 272	8.4% 8.4%	1.07 [0.74, 1.55] 1.07 [0.74, 1.55]	
Total events Heterogeneity: Not ap	31 plicable	(D - 0)	65	212	0.17/0	101 [0114, 100]	
restior overall ellect.	2=0.37	(P = 0.7	0				
1.5.2 Viral vector vac	cines						
Frater 2021	24	51	32	49	9.2%	0.72 [0.51, 1.03]	
Madhi 2021	1	52	1	58	0.2%	1.12 [0.07, 17.39]	← →
Subtotal (95% CI)		103		107	9.3%	0.73 [0.51, 1.03]	◆
Total events	25		33				
Heterogeneity: Tau² =	0.00; Ch	i² = 0.1	0, df = 1 (P = 0.7	75); I ² = 0	%		
Test for overall effect:	Z=1.78	(P = 0.0)7)				
4.F.2 Inactinated upo	ainaa						
1.5.3 Inactivated vac	cines				4.000	4 05 10 70 0 4 51	
Cal 2021	14	50	32	143	4.0%	1.25 [0.73, 2.15]	
Huang 2021	42	129	22	23	7.1%	0.78 [0.52, 1.18]	
Netto 2021 Zeu 2024	44	189	95	290	12.3%	0.73 [0.53, 0.99]	
ZUU ZUZI Subtotal (95% CI)	4	40	0	38 530	24.1%	0.35 [0.17, 1.81]	
Total events	104	414	155	550	24.170	0.01[0.04, 1.04]	•
Hotorogonoity: Tou2-	104 0.011 Ch	iZ – 0 A	2 df = 2 /P = 0.3) 2)· IZ = 1	204		
Test for overall effect:	7 - 1.67	(P – 0.4	2, ui = 5 (r = 0.5 19)	55),1 = 1	270		
restion overall effect.	2 - 1.07	(i = 0.0	,3)				
1.5.4 Protein subunit	vaccines	5					
Cheng 2021	39	58	2381	3295	35.4%	0.93 [0.78, 1.12]	
Shinde 2021	61	142	143	329	22.7%	0.99 [0.79, 1.24]	-+-
Subtotal (95% CI)		200		3624	58.1 %	0.95 [0.83, 1.10]	◆
Total events	100		2524				
Heterogeneity: Tau² =	0.00; Ch	i² = 0.1	8, df = 1 (P = 0.6	67); I ² = 0	%		
Test for overall effect:	Z = 0.67	(P = 0.5	50)				
Total (95% CI)		838		4533	100.0%	0.90 [0.81, 1.00]	•
Total events	260		2777			size [size i, noo]	•
Heterogeneity: Tau ² =	: 0.00: Ch	i ^z = 7.6	1. df = 8 (P = 0.4	$(7): ^2 = 0$	%		
Test for overall effect:	Z = 1.91	(P = 0.0)6)				0.1 0.2 0.5 1 2 5 10
Test for subgroup diff	erences:	Chi ² =	3.57, df = 3 (P =	0.31), I ^z	= 15.9%		PLVVH HIV negative people

Figure 12: Forest plot of local reactions between PLWH and HIV negatives after 2nd dose of SARS-CoV-2 vaccines

Study or Subgroup	PLW Events	H Total	HIV negative p	eople	Woight	Risk Ratio	Risk Ratio			
1.7.1 mRNA vaccines	LVCIUS	Total	Lvents	Total	weight	M-n, Kanuom, 55% Ci	M-n, Random, 55% Cr			
Bergman 2021	2	90	Ω	90	0.3%	5.00 (0.24, 102,71)				
Lew 2021	60	121	131	272	21.7%	1.03 [0.83, 1.28]	_ + _			
Subtotal (95% CI)		211		362	22.0 %	1.09 [0.61, 1.93]	-			
Total events	62		131							
Heterogeneity: Tau ² =	0.08; Ch	i ² = 1.0	6, df = 1 (P = 0.3	30); I ² = 6	%					
Test for overall effect:	Z = 0.29 ((P = 0.7	(7)							
1.7.2 Viral vector vac	cines									
Frater 2021	22	51	32	49	12.4%	0.66.00.45.0.961				
Madhi 2021	21	52	32	58	11.3%	0.73 [0.49, 1.10]	_ _			
Subtotal (95% CI)		103		107	23.7%	0.69 [0.53, 0.91]	•			
Total events	43		64							
Heterogeneity: Tau² =	0.00; Ch	i ² = 0.1	3, df = 1 (P = 0.7	'1); I ² = 0	%					
Test for overall effect:	Z = 2.62 ((P = 0.0)09)							
173 Inactivated vac	nines									
Cai 2021	11	50	25	1/3	5.7%	1 26 10 67 2 371				
Huang 2021	22	129	10	53	5.1%	0.90 [0.46, 1.78]				
Zou 2021	1	46	3	38	0.5%	0.28 [0.03, 2.54]	←			
Subtotal (95% CI)		225		234	11.3%	1.02 [0.65, 1.60]				
Total events	34		38							
Heterogeneity: Tau² =	0.00; Ch	i² = 1.9	0, df = 2 (P = 0.3	89); I ² = 0	%					
Test for overall effect:	Z = 0.08 ((P = 0.9	33)							
174 Protein subunit	vaccines									
Cheng 2021	37	, 58	1774	3295	72.2%	1 18 0 97 1 44	↓_			
Shinde 2021	56	142	127	329	19.7%		_ _			
Subtotal (95% CI)		200		3624	43.0%	1.12 [0.96, 1.30]	◆			
Total events	93		1901							
Heterogeneity: Tau ² =	0.00; Ch	i² = 0.9	3, df = 1 (P = 0.3	33); I z = 0	%					
Test for overall effect:	Z=1.43 ((P = 0.1	5)							
Total (95% CI)		730		4327	100.0%	0 97 [0 82 4 44]	▲			
Total events	232	155	2134	4521	100.070	0.07 [0.02, 1.14]	T			
Heterogeneity: Tau ² =	0.02: Chi	i ² = 12	98. df = 8 (P = 0	.11): P =	38%					
Test for overall effect:	0.1 0.2 0.5 1 2 5 10									
Test for subgroup differences: Chi ² = 8.98, df = 3 (P = 0.03), l ² = 66.6%										

Figure 13: Forest plot of systemic reactions between PLWH and HIV negatives after 2nd dose SARS-CoV-2 vaccines

Study or Subgroup	CD4 count<500 cells Events	s/mm ³ Total	CD4 count>=500 cells	s/mm ³ Total	Weight	Risk Ratio M.H. Random, 95% Cl	Risk Ratio M.H. Random, 95% Cl	
1.8.1 mRNA vaccines	i	Total	Liono	rotar	roight	in fig failude fig 6678 of		-
Antinori 2021	79	83	76	77	29.2%	0.96 [0.91, 1.02]	-	
Nault 2021	9	18	76	82	13.5%	0.54 [0.34, 0.86]		
Subtotal (95% CI)		101		159	42.6%	0.73 [0.24, 2.21]		
Total events	88		152					
Heterogeneity: Tau² =	0.61; Chi ² = 22.33, df =	= 1 (P < 0	.00001); I² = 96%					
Test for overall effect:	Z = 0.56 (P = 0.58)							
1.8.2 Viral vector vac	cines							
Khan 2021	4	10	21	24	6.9%	0.46 [0.21, 0.99]		
Subtotal (95% CI)		10		24	6.9%	0.46 [0.21, 0.99]		
Total events	4		21					
Heterogeneity: Not ap	plicable							
Test for overall effect:	Z = 1.98 (P = 0.05)							
1.8.3 Inactivated vac	cines							
Huang 2021	23	32	86	97	23.0%	0.81 [0.65, 1.02]		
Netto 2021	53	64	142	151	27.5%	0.88 [0.78, 0.99]		
Subtotal (95% CI)		96		248	50.5 %	0.87 [0.78, 0.96]	•	
Total events	76		228					
Heterogeneity: Tau ² =	0.00; Chi² = 0.43, df =	1 (P = 0.5	i1); I² = 0%					
Test for overall effect:	Z = 2.70 (P = 0.007)							
Total (95% CI)		207		431	100.0%	0.79 [0.63, 1.00]	•	
Total events	168		401					
Heterogeneity: Tau ² =	0.05; Chi ² = 32.62, df =	= 4 (P < 0	.00001); I² = 88%					
Test for overall effect:	Z = 1.95 (P = 0.05)						CD4 count<500 CD4 count >= 500	
Test for subgroup diff	erences: Chi ^z = 2.64, d	lf = 2 (P =	0.27), I ² = 24.2%					

Figure 14: Pooled results of IgG seroconversion among PLWH based on CD4 count <500 or \ge 500 cells/µL

	CD4<2	200	CD4>=	200		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.12.1 mRNA vaccines							
Antinori 2021 Subtotal (95% CI)	26	30 30	129	130 130	62.0% 62.0 %	0.87 [0.76, 1.01] 0.87 [0.76, 1.01]	•
Total events	26		129				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z = 1.88	(P = 0.0)6)				
1.12.2 Viral vector va	iccines						
Khan 2021	4	10	21	24	38.0%	0.46 [0.21, 0.99]	
Subtotal (95% CI)		10		24	38.0 %	0.46 [0.21, 0.99]	-
Total events	4		21				
Heterogeneity: Not ap	plicable						
Test for overall effect:	Z=1.98	(P = 0.0)5)				
Total (95% CI)		40		154	100.0%	0.68 [0.32, 1.45]	-
Total events	30		150				
Heterogeneity: Tau ^z =	0.23; Ch	i² = 3.9					
Test for overall effect:	Z = 0.99	(P = 0.3)	CD4<200 CD4>=200				
Test for subgroup diff	erences:	Chi²=	55, 200 OBT-200				

Figure 15: Pooled results of IgG seroconversion among PLWH based on CD4 count <200 or \ge 200 cells/µL

	CD4<	500	CD4>=	500		Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-I	l, Random, 95% Cl			
1.9.1 mRNA vaccines	5										
Antinori 2021	66	81	67	72	75.6%	0.88 [0.78, 0.99]					
Jedicke 2021	5	16	14	40	1.6%	0.89 [0.39, 2.07]					
Subtotal (95% CI)		97		112	77.2%	0.88 [0.78, 0.99]		•			
Total events	71		81								
Heterogeneity: Tau ² = 0.00; Chi ² = 0.00, df = 1 (P = 0.96); i ² = 0%											
Test for overall effect: Z = 2.16 (P = 0.03)											
1.9.2 Inactivated vac	cines										
Netto 2021	38	64	115	151	22.8%	0.78 [0.62, 0.97]					
Subtotal (95% CI)		64		151	22.8%	0.78 [0.62, 0.97]		•			
Total events	38		115								
Heterogeneity: Not applicable											
Test for overall effect:	Z= 2.20	(P = 0.0))3)								
Total (95% CI)		161		263	100.0 %	0.85 [0.77, 0.95]		•			
Total events	109		196								
Heterogeneity: Tau ² =	0.00; Ch	i² = 1.0	4, df = 2 (P = 0.5	9); I ² = 0%	6			<u>_</u>	10	
Test for overall effect:	Z= 2.95	(P = 0.0))03)			0.1 0.2 0 CE	4<500 CD4>=500	5	10		
Test for subaroup diff	erences:	Chi ² =	0.82, df=	1 (P = 1)	0.36), l ² =	0%	01				

Figure 16: Pooled results of neutralizing antibodies response among PLWH (<500 vs $\geq 500 \text{ cells}/\mu\text{L})$



Figure 17 a: Meta-regression of Median age (years) and SARS-CoV-2 IgG antibodies level (BAU/ml). Figure 17 b: Median CD4(cells/µL) and SARS-CoV-2 IgG antibodies level (BAU/ml)

Publication bias



Figure 18a: Funnel plot of IgG seroconversion after the second dose of SARS-CoV-2 vaccination. Figure 18b: Funnel plot of IgG antibodies level (BAU/ml) after the second dose of SARS-CoV-2 vaccination